Sort by:
49–64 of 4630 Results
-
SaleComprid 80 mgComprid 80 mg is a medicine that reduces blood sugar levels (oral antidiabetic medicine belonging to the sulphonylurea group). Comprid 80 mg is used in a certain form of diabetes (type 2 diabetes Mellitus) in adults, when diet, exercise and weight loss alone do not have an adequate effect on keeping blood sugar at the correct level.Theropeutic ClassSulfonylureasPharmacologyComprid 80 mg is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic ?-cells by facilitating Ca2+ transport across the ?-cell membranes and decreases hepatic glucose output.Dosage & Administration of Comprid 80 mgOral route: The usual initial dose is 40 to 80 mg daily. The dose can be increased upto 320 mg daily in divided doses when needed. The drug should be taken before meal. For children Comprid 80 mg is not used because it is contraindicated in juvenile- onset diabetes.Dosage of Comprid 80 mgFilm-coated tablet: The usual initial dose is 40 to 80 mg daily. The dose can be increased up to 320 mg daily in divided doses when needed. The drug should be taken before meal. For children, Comprid 80 mg is not used because it is contraindicated in juvenile-onset diabetes.Modified release preparation: Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. The dose is determined by the doctor, depending on your blood and possibly urine sugar levels. Change in external factors (weight reduction, lifestyle, stress) or improvements in the blood sugar control may require changed Comprid 80 mg doses.The recommended daily dose is one to four tablets (maximum 120 mg) in a single intake at breakfast time. This depends on the response to treatment. Comprid 80 mg MR tablet is for oral use. Take your tablet(s) with a glass of water at breakfast time (and preferably at the same time each day). Swallow your whole tablet(s) in one piece. Do not chew or crush. You must always eat a meal after taking your tablet(s).If a combination therapy of Comprid 80 mg with metformin, an alpha-glucosidase inhibitor, a thiazolidinedione, a dipeptidyl peptidase-4 inhibitor a GLP-1 receptor agonist or insulin is initiated your doctor will determine the proper dose of each medicine individually for you. If you notice that your blood sugar levels are high although you are taking the medicine as prescribed, you should contact your doctor or pharmacist.If you take more Comprid 80 mg tablets than you should: If you take too many tablets, contact your doctor or the nearest hospital Accident & Emergency department immediately. The signs of overdose are those of low blood sugar (hypoglycaemia). The symptoms can be helped by taking sugar (4 to 6 lumps) or sugary drinks straight away, followed by a substantial snack or meal. If the patient is unconscious immediately inform a doctor and call the emergency services. The same should be done if somebody, (for instance a child), has taken the product unintentionally. Unconscious patients must not be given food or drink. It should be ensured that there is always a pre-informed person that can call a doctor in case of emergency.If you forget to take Comprid 80 mg tablet: It is important to take your medicine every day as regular treatment works better. However, if you forget to take a dose of Comprid 80 mg MR tablet, take the next dose at the usual time. Do not take a double dose to make up for a forgotten dose.If you stop taking Comprid 80 mg MR tablet: As the treatment for diabetes is usually lifelong, you should discuss with your doctor before stopping this medicinal product. Stopping could cause high blood sugar (hyperglycaemia) which increases the risk of developing complications of diabetes. If you have any further questions on the use of this product, ask your doctor or pharmacist.Interaction of Comprid 80 mgOther medicines and Comprid 80 mg: Tell your doctor or pharmacist if you are taking or have recently taken any other medicines. The blood sugar lowering effect of Comprid 80 mg may be strengthened and signs of low blood sugar levels may occur when one of the follow ng medicines is taken: other medicines used to treat high blood sugar (oral antidiabetics, GLP-1 receptor agonists or insulin), antibiotics (sulphonamides, clarithromycin) medicines to treat high blood pressure or heart failure (beta-blockers. ACE-inhibitors such as captopril, or enalapril) medicines to treat fungal infections (miconazole, fluconazole) medicines to treat ulcers in the stomach or duodenum (H2 receptor antagonists), medicines to treat depression (monoamine oxidase inhibitors) painkiller or antirheumatics (phenylbutazone, ibuprofen) medicines containing alcohol The blood-glucose-lowering effect of Comprid 80 mg may be weakened and raised blood sugar levels may occur when one of the following medicines is taken: medicines to treat disorders of the central nervous system (chlorpromazine) medicines reducing inflammation (corticosteroids) medicines to treat asthma or used during labour (intravenous salbutamol, ritodrine and terbutaline) medicines to treat breast disorders, heavy menstrual bleeding and endometriosis (danazol) St John's Wort- Hypericum perforatum- preparations Blood glucose disturbance (low blood sugar and high blood sugar) can occur when a medicine belonging to a class of antibiotics called fluoroquinolones is taken at the same time as Comprid 80 mg especially in elderly patients.Comprid 80 mg may increase the effects of medicines that reduce blood clotting (warfarin). Consult your doctor before you start taking another medicinal product. If you go into hospital tell the medical staff you are taking Comprid 80 mg.Comprid 80 mg with food and drink: Comprid 80 mg can be taken with food and non-alcoholic drinks. Drinking alcohol is not recommended as it can alter the control of your diabetes in an unpredictable manner.Driving and using machines: Your ability to concentrate or react may be impaired if your blood sugar is too low (hypoglycaemia), or too high (hyperglycaemia) or if you develop visual problems as a result of such conditions. Bear in mind that you could endanger yourself or others (for instance when driving a car or using machines). Please ask your doctor whether you can drive a car if you: have frequent episodes of low blood sugar (hypoglycaemia) have few or no warning signals of low blood sugar (hypoglycaemia) Comprid 80 mg contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.ContraindicationsDo not take Comprid 80 mg: if you are allergic to Comprid 80 mg or to other medicines of the same group (sulfonylurea), or to other related medicines (hypoglycaemic sulfonamides) if you have insulin-dependent diabetes (type 1) if you have ketone bodies and sugar in your urine (this may mean you have diabetic ketoacidosis), a diabetic pre-coma or coma if you have severe kidney or liver disease if you are taking medicines to treat fungal infections if you are breastfeeding Side Effects of Comprid 80 mgLike all medicines, Comprid 80 mg can cause side effects, although not everybody gets them. The most commonly observed side effect is low blood sugar (hypoglycaemia). If left untreated these symptoms could progress to drowsiness, loss of consciousness or possibly coma. If an episode of low blood sugar is severe or prolonged, even if it is temporarily controlled by eating sugar, you should seek immediate medical attention.Liver disorders: There have been isolated reports of abnormal iiver function, which can cause yellow skin and eyes. If you get this, see your doctor immediately. The symptoms generally disappear if the medicine is stopped. Your doctor will decide whether to stop your treatment.Skin disorders: Skin reactions such as rash, redness, itching, hives, blisters, angioedema (rapid swelling of tissues such as eyelids, face, lips, mouth, tongue or throat that may result in breathing difficulty) have been reported. Rash may progress to widespread blistering or peeling of the skin. If you develop this, stop taking, seek urgent advice from a doctor and tell him that you are taking this medicine. Exceptionally, signs of severe hypersensitivity reactions have been reported: initially as flu-like symptoms and a rash on the face then an extended rash with a high temperature.Blood disorders: Decrease in the number of cells in the blood (e.g. platelets, red and white blood cells) which may cause paleness, prolonged bleeding, bruising, sore throat and fever have been reported. These symptoms usually vanish when the treatment is discontinued.Digestive disorders: Abdominal pain, nausea, vomiting, indigestion, diarrhoea, and constipation. These effects are reduced when Comprid 80 mg is taken with a meal as recommended.Eye disorders: Your vision may be affected for a short time especially at the start of treatment. This effect is due to changes in blood sugar levels. As for another sulfonylurea, the following adverse events have been observed: cases of severe changes in the number of blood cells and allergic inflammation of the wall of blood vessels, reduction in blood sodium (hyponatraemia), symptoms of liver impairment (for instance jaundice) which in most cases disappeared after withdrawal of the sulfonylurea, but may lead to life-threatening liver failure in isolated cases.Reporting of side effects: If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.Pregnancy & LactationComprid 80 mg is contraindicated in pregnant women. It should not be used in breast feeding mother.Precautions & WarningsTalk to your doctor before taking Comprid 80 mg. You should observe the treatment plan prescribed by your doctor to achieve proper blood sugar levels. This means, apart from regular tablet intake, to observe the dietary regimen, have physical exercise and, where necessary, reduce weight During Comprid 80 mg treatment regular monitoring of your blood (and possibly urine) sugar level and also your glycated haemoglobin (HbA1c) is necessary. In the first few weeks of treatment, the risk of having reduced blood sugar levels (hypoglycaemia) may be increased. So particularly close medical monitoring is necessary.Low blood sugar (Hypoglycaemia) may occur: if you take meals irregularly or skip meals altogether, if you are fasting if you are malnourished if you change your diet if you increase your physical activity and carbohydrate intake does not match this increase, if you drink alcohol, especially in combination with skipped meals, if you take other medicines or natural remedies at the same time, if you take too high doses of Comprid 80 mg, if you suffer from particular hormone-induced disorders (functional disorders of the thyroid gland, pituitary gland or adrenal cortex), if your kidney function or liver function is severely decreased. if you have low blood sugar you may have the following symptoms: headache, intense hunger, nausea, vomiting, weariness, sleep disorders, restlessness, aggressiveness, poor concentration, reduced alertness and reaction time, depression, confusion, speech or visual disorders, tremor, sensory disturbances, dizziness and helplessness.The following signs and symptoms may also occur: sweating, clammy skin, anxiety, fast or irregular heartbeat, high blood pressure, sudden strong pain in the chest that may radiate into nearby areas (angina pectoris).If blood sugar levels continue to drop you may suffer from considerable confusion (delirium), develop convulsions, lose self-control, your breathing may be shallow and your heartbeat slowed down, you may become unconscious.In most cases the symptoms of low blood sugar vanish very quickly when you consume .some form of sugar, (for instance, glucose tablets, sugar cubes, sweet juice, sweetened tea).You should therefore always carry some form of sugar with you (glucose tablets, sugar cubes). Remember that artificial sweeteners are not effective. Please contact your doctor or the nearest hospital if taking sugar does not help or if the symptoms recur.Symptoms of low blood sugar may be absent, less obvious or develop very slowly or you are not aware in time that your blood sugar level has dropped. This may happen if you are an elderly patient taking certain medicines (for instance those acting on the central nervous system and beta-blockers).If you are in stressful situations (e.g. accidents, surgical operations, fever etc.) your doctor may temporarily switch you to insulin therapy.Symptoms of high blood sugar (hyperglycaemia) may occur when Comprid 80 mg has not yet sufficiently reduced the blood sugar when you have not complied with the treatment plan prescribed by your doctor if you take St. John?s Wort (Hypericum perforatum) preparations or in special stress situations. These may include thirst, frequent urination, dry mouth, dry itchy skin, skin infections and reduced performance.Blood glucose disturbances (low blood sugar and high bold sugar) can occur when Comprid 80 mg is prescribed at the same time as medicines to a class of antibiotics called fluoroquinolone, especially in elderly patients. In this case, your doctor will remind you of the importance of monitoring your blood glucose.If you have a family history of or know you have the hereditary condition glucose-6-phosphate dehydrogenase (G6PD) deficiency (abnormality of red blood cells), lowering of the haemoglobin level and breakdown of red blood cells (haemolytic anaemia) can occur. Contact your doctor before taking this medicinal product.Comprid 80 mg is not recommended for use in children due to lack of data.Storage ConditionsKeep out of the reach and sight of children. Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month. Store below 30?C. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.Drug ClassesSulfonylureasMode Of ActionComprid 80 mg is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful hematological properties. It stimulates the release of insulin from pancreatic ?-cells by facilitating Ca+2? transport across the ?-cell membranes and decreases hepatic glucose output.PregnancyComprid 80 mg is not recommended for use during pregnancy. If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine. You must not take Comprid 80 mg while you are breastfeeding.Sku: 1736108001-4618
Comprid80 mg
₦4,400.00Original price was: ₦4,400.00.₦3,960.00Current price is: ₦3,960.00.₦4,400.00Original price was: ₦4,400.00.₦3,960.00Current price is: ₦3,960.00. Add to basket Quick View -
SaleCildip 5 mgCildip 5 mg is indicated for the management of hypertension for end-organ protection. It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cildip 5 mg has been increasingly used in patients with chronic kidney diseaseHypertension is the term used to ... Read moreCildip 5 mg is indicated for the management of hypertension for end-organ protection. It is reported to be useful in elderly patients and in those with diabetes and albuminuria. Cildip 5 mg has been increasingly used in patients with chronic kidney diseaseHypertension is the term used to describe the presence of high blood pressure. The blood pressure is generated by the force of the blood pumped from the heart against the blood vessels. Thus hypertension is caused when there is too much pressure on the blood vessels and this effect can damage the blood vesselTheropeutic ClassCalcium-channel blockersPharmacologyCildip 5 mg is a dihydropyridine calcium-channel blocker. Cildip 5 mg binds to the dihydropy-ridine binding sites of the L-type voltage dependent calcium channel and inhibits Ca2+ influx across the cell membranes of vascular smooth muscle cells via this channel, consequently vascular smooth muscle is relaxed, causing vasodilation. Cildip 5 mg inhibits Ca2+ influx via N-type voltage dependent calcium channels in the sympathetic nerve cell membrane. The inhibition of Ca2+ influx via N-type voltage dependent calcium channel was observed over a similar range of drug concentrations to those inhibiting L-type voltage dependent Ca2+ channels. Consequently, release of norepinephrine from sympathetic nerve terminals would be inhibited. Cildip 5 mg is considered to suppress the reflex increase in heart rate after blood pressure reduction.Dosage & Administration of Cildip 5 mgAdults: 5-10 mg once daily after breakfast. Maximum dose: 20 mg once daily. The safety of Cildip 5 mg in pediatric patients has not been established.Use in the elderly: Since the elderly may be more susceptible to hypotension, therapy should be initiated with the lowest possible dose (5 mg).Dosage of Cildip 5 mgAdults: 5-10 mg once daily after breakfast. Maximum dose: 20 mg once daily. Pediatric use: The safety of Cildip 5 mg in pediatric patients has not been established.Elderly use: Since the elderly may be more susceptible to hypotension, therapy should be initiated with the lowest possible dose (5 mg).Interaction of Cildip 5 mgOther anti-hypertensive, antipsychotics that cause hypotension, quinidine, carbamazepine, phenytoin, rifampicin, cimetidine, erythromycin.ContraindicationsCildip 5 mg is contraindicated in patients with known sensitivity to Cildip 5 mg or any of the excipients or patients having cardiogenic shock, recent MI or acute unstable angina and severe aortic stenosis.Side Effects of Cildip 5 mgThe most common side effects of Cildip 5 mg are: Dizziness; flushing; headache; hypotension; peripheral oedema; palpitations; GI disturbances; increased micturition frequency; lethargy; eye pain; depression.Pregnancy & LactationCildip 5 mg should not be administered in pregnant woman or woman having possibilities of being pregnant. It is also advisable to avoid the administration of Cildip 5 mg to nursing mothers. However, if the administration is indispensable, the patient should be instructed to discontinue lactation.Precautions & WarningsCildip 5 mg should be administered with care in the following patients: patients with serious hepatic dysfunction, patients with a history of serious adverse reactions to calcium antagonists. During the discontinuation, the dosage should be gradually decreased under close observation.Storage ConditionsStore below 30?C, protected from light and moisture. Keep away from reach out of the children.Drug ClassesCalcium-channel blockersMode Of ActionCildip 5 mg is a dihydropyridine calcium-channel blocker. Cildip 5 mg binds to the dihydropy-ridine binding sites of the L-type voltage dependent calcium channel and inhibits Ca2+ influx across the cell membranes of vascular smooth muscle cells via this channel, consequently vascular smooth muscle is relaxed, causing vasodilation. Cildip 5 mg inhibits Ca2+ influx via N-type voltage dependent calcium channels in the sympathetic nerve cell membrane. The inhibition of Ca2+ influx via N-type voltage dependent calcium channel was observed over a similar range of drug concentrations to those inhibiting L-type voltage dependent Ca2+ channels. Consequently, release of norepinephrine from sympathetic nerve terminals would be inhibited. Cildip 5 mg is considered to suppress the reflex increase in heart rate after blood pressure reduction.PregnancyCildip 5 mg should not be administered in pregnant woman or woman having possibilities of being pregnant. It is also advisable to avoid the administration of Cildip 5 mg to nursing mothers. However, if the administration is indispensable, the patient should be instructed to discontinue lactation.Sku: 1736107998-4617
Cildip5 mg
₦6,160.00Original price was: ₦6,160.00.₦5,544.00Current price is: ₦5,544.00.₦6,160.00Original price was: ₦6,160.00.₦5,544.00Current price is: ₦5,544.00. Add to basket Quick View -
SaleTiginor 10 mgTiginor 10 mg is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B (Apo-B) and triglycerides levels in following diseases when response to diet and other non-pharmacological measures is inadequate. To reduce total cholesterol and LDL cholesterol in patients with heterozygous and homozygous familial hypercholesterolaemia. To reduce elevated cholesterol and triglycerides in patient with mixed dyslipidemia (Fredrickson Type Ia and Ib). For the treatment of patients with elevated serum triglyceride levels in hypertriglyceridaemia (Fredrickson Type IV). For the treatment of patients with dysbetalipoproteinaemia (Fredrickson Type III). To reduce cardiac ischaemic events in patients with asymptomatic or mild to moderate symptomatic coronary artery disease with elevated LDL-cholesterol level. To reduce total and LDL-cholesterol concentrations patients with hypercholesterolemia associated with or exacerbated by diabetes mellitus or renal transplantation.Theropeutic ClassOther Anti-anginal & Anti-ischaemic drugs, StatinsPharmacologyAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.Dosage & Administration of Tiginor 10 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Dosage of Tiginor 10 mgPrimary hypercholesterolaemia and combined hyperlipidaemia- Adults: Usually 10 mg once daily; if necessary, may be increased at intervals of at least 4 weeks to max. 80 mg once daily. Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 20 mg once daily. Familial hypercholesterolaemia- Adults: Initially 10 mg daily, increased at intervals of at least 4 weeks to 40 mg once daily; if necessary, further increased to max. 80 mg once daily (or 40 mg once daily combined with anion-exchange resin in heterozygous familial hypercholesterolaemia). Child (10-18 years): Initially 10 mg once daily, increased if necessary at intervals of at least 4 weeks to usual max. 80 mg once daily. Prevention of cardiovascular events- Adults: Initially 10 mg once daily adjusted according to response.Interaction of Tiginor 10 mgThe risk of myopathy during treatment with Atorvastatin is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals and niacin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives or hypoglycemic agents. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.ContraindicationsTiginor 10 mg should not be used in patient with hypersensitivity to any component of this medication. It's contraindicated in active liver disease or unexplained persistent elevations of serum transaminases. It is also contraindicated in patient with history of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors.Side Effects of Tiginor 10 mgTiginor 10 mg is generally well-tolerated. The most frequent side effects related to Tiginor 10 mg are constipation, flatulence, dyspepsia, abdominal pain. Other side effects includes infection, headache, back pain, rash, asthenia, arthralgia, myalgia.Pregnancy & LactationTiginor 10 mg is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures during Atorvastatin therapy. If the woman become pregnant while taking Tiginor 10 mg, it should be discontinued.Precautions & WarningsLiver effects: Liver function tests should be performed before the initiation of treatment and periodically thereafter. Atorvastatin should be used with caution in patients who consume substantial quantities of alcohol or have a history of liver disease. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.Overdose Effects of Tiginor 10 mgSpecific treatment is not available for atorvastatin overdose. The patient should be treated symptomatically and supportive measures instituted, as required. Liver function tests should be performed and serum CK levels should be monitored. Due to extensive atorvastatin binding to plasma proteins, hemodialysis is not expected to significantly enhance atorvastatin clearance.Storage ConditionsKeep in a dry place away from light and heat. Keep out of the reach of children.Use In Special PopulationsGeriatric Use: Of the 39,828 patients who received Atorvastatin in clinicalstudies, 15,813 (40%) were ?65 years old and 2,800 (7%) were ?75 years old. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinicalexperience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older adults cannot be ruled out. Since advanced age (?65 years) is a predisposing factor for myopathy, Atorvastatin?should be prescribed with caution in the elderly.Hepatic Impairment: Atorvastatin?is contraindicated in patients with active liver disease whichmay include unexplained persistent elevations in hepatic transaminase levelsDrug ClassesOther Anti-anginal & Anti-ischaemic drugs, StatinsMode Of ActionAtorvastatin is a selective inhibitor of HMG-CoA reductase. This enzyme is the rate-limiting enzyme responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Atorvastatin lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and increases the number of hepatic LDL receptors on the cell surface for enhanced uptake and catabolism of LDL.PregnancyPregnancy: Atorvastatin is contraindicated during pregnancy. Safety in pregnant women has not been established. No controlled clinical trials with atorvastatin have been conducted in pregnant women. Rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors have been received. Animal studies have shown toxicity to reproduction. Maternal treatment with atorvastatin may reduce the fetal levels of mevalonate which is a precursor of cholesterol biosynthesis. Atorvastatin should not be used in women who are pregnant, trying to become pregnant or suspect they are pregnant. Treatment with atorvastatin should be suspended for the duration of pregnancy or until it has been determined that the woman is not pregnantLactation: It is not known whether atorvastatin or its metabolites are excreted in human milk. In rats, plasma concentrations of atorvastatin and its active metabolites are similar to those in milk. Because of the potential for serious adverse reactions, women taking atorvastatin should not breastfeed their infants. Atorvastatin is contraindicated during breastfeeding.Pediatric UsesHepatic impairment: Tiginor 10 mg should be used with caution in patients with hepatic impairment. Pediatric use: For patients aged 10 years and above, the recommended starting dose of atorvastatin is 10 mg per day with titration up to 20 mg per day. Tiginor 10 mg is not indicated in the treatment of patients below the age of 10 years.Sku: 1736107995-4616
Tiginor10 mg
₦6,325.00Original price was: ₦6,325.00.₦5,692.50Current price is: ₦5,692.50.₦6,325.00Original price was: ₦6,325.00.₦5,692.50Current price is: ₦5,692.50. Add to basket Quick View -
SaleBetaloc 25 mgln the management of hypertension and angina pectoris. Cardiac arrhythmias, especially supraventricular tachyarrhythmias. Adjunct to the treatment of hyperthyroidism. Early intervention with Metoprolol in acute myocardial infarction reduces infarct size and the incidence of ventricular fibrillation ... Read moreln the management of hypertension and angina pectoris. Cardiac arrhythmias, especially supraventricular tachyarrhythmias. Adjunct to the treatment of hyperthyroidism. Early intervention with Metoprolol in acute myocardial infarction reduces infarct size and the incidence of ventricular fibrillation. Pain relief may also decrease the need for opiate analgesics. Metoprolol has been shown to reduce mortality when administered to patients with acute myocardial infarction.Theropeutic ClassBeta-adrenoceptor blocking drugs, Beta-blockersPharmacologyMetoprolol is a selective beta1-blocker. Metoprolol reduces or inhibits the agonistic effect on the heart of catecholamines (which are released during physical and mental stress). This means that the usual increase in heart rate, cardiac output, cardiac contractility and blood pressure, produced by the acute increase in catecholamines, is reduced by Metoprolol. Metoprolol interferes less with Insulin release and carbohydrate metabolism than do non-selective beta-blockers. Metoprolol interferes much less with the cardiovascular response to hypoglycaemia than do non-selective beta-blockers.Dosage & Administration of Betaloc 25 mgOral- Hypertension: Total daily dosage Metoprolol 100-400 mg to be given as a single or twice daily dose. The starting dose is 100 mg (two Metoprolol-50 tablets) per day. This may be increased by 100 mg per day at weekly intervals. lf full control is not achieved using a single daily dose, a b.i.d. regimen should be initiated. Combination therapy with a diuretic or other anti-hypertensive agent may also be considered.Angina: Usually Metoprolol 50 mg (one Metoprolol-50 tablet) to 100 mg (two Metoprolol-50 tablets)?twice or three times daily.Cardiac arrhythmias: Metoprolol 50 mg (one Metoprolol-50 tablet) b.i.d or t.i.d should usually control the condition. It necessary the dose can be increased up to 300 mg per day in divided doses. Following the treatment of an acute arrhythmia with Metoprolol injection, continuation?therapy with Metoprolol tablets should be initiated 4-6 hours later. The initial oral dose should not exceed 50 mg t.i.d.Hyperthyroidism: Metoprolol 50 mg (one Metoprolol-50 tablet) four times a day.The dose should be?reduced as the euthyroid state is achieved.Myocardial infarction: Orally, therapy should commence 15 minutes after the last injection with?50 mg every 6 hours for 48 hours. Patients who fail to tolerate the full intravenous dose should be?given half the suggested oral dose. Maintenance ? The usual maintenance dose is 200 mg daily?given in divided doses. Elderly? There are no special dosage requirements in otherwise healthy?elderly patients. Signidcant hepatic dysfunction: A reduction in dosage may be necessary. Injection- Arrhythmias: By intravenous injection, up to 5 mg at a rate of 1-2 mg/minute, repeated after 5 minutes if necessary, total dose 10-15 mg. In surgery: By slow intravenous injection 2-4 mg at induction or to control arrhythmias developing during anaesthesia; 2 mg doses may be repeated to a maximum of 10 mg. Myocardial Infarction: Early intervention within 12 hours of infarction, by intravenous injection 5 mg every 2 minutes to a maximum of 15 mg, followed after 15 minutes by 50 mg by mouth every 6 hours for 48 hours; maintenance 200 mg daily in divided doses.Impaired Renal Function: Dose adjustment is not needed in patients with impaired renal function. Impaired Hepatic Function: Dose adjustment is not normally needed in patients suffering from liver cirrhosis because Metoprolol has low protein binding (5-10%). When there are signs of serious impairment of liver function (e.g. shunt-operated patients), a reduction in dose should be considered. Elderly: Dose adjustment is not needed.Dosage of Betaloc 25 mgFilm-coated tablet- Hypertension: Total daily dosage Metoprolol 100-400 mg to be given as a single or twice-daily dose. The starting dose is 100 mg (two Metoprolol-50 tablets) per day. This may be increased by 100 mg per day at weekly intervals. lf full control is not achieved using a single daily dose, a b.i.d. regimen should be initiated. Combination therapy with a diuretic or other antihypertensive agents may also be considered. Angina: Usually Metoprolol 50 mg (one Metoprolol-50 tablet) to 100 mg (two Metoprolol-50 tablets)?twice or three times daily. Cardiac arrhythmias: Metoprolol 50 mg (one Metoprolol-50 tablet) b.i.d or t.i.d should usually control the condition. It is necessary the dose can be increased up to 300 mg per day in divided doses. Following the treatment of an acute arrhythmia with Metoprolol injection, continuation therapy with Metoprolol tablets should be initiated 4-6 hours later. The initial oral dose should not exceed 50 mg t.i.d. Hyperthyroidism: Metoprolol 50 mg (one Metoprolol-50 tablet) four times a day. The dose should be reduced as the euthyroid state is achieved. Myocardial infarction: Orally, therapy should commence 15 minutes after the last injection with 50 mg every 6 hours for 48 hours. Patients who fail to tolerate the full intravenous dose should be given half the suggested oral dose. Maintenance- The usual maintenance dose is 200 mg daily given in divided doses. Elderly? There are no special dosage requirements in otherwise healthy elderly patients. Significant hepatic dysfunction: A reduction in dosage may be necessary. Extended-release tablet- Hypertension: The usual initial dosage is 25 to 100 mg daily in a single dose, whether used alone or added to a diuretic. Angina Pectoris: The dosage of extended-release Metoprolol Succinate should be individualized. The usual initial dosage is 100 mg daily, in a single dose. Heart Failure: The recommended starting dose of sustained-release Metoprolol Succinate is 25 mg once daily for two weeks in patients with NYHA class II heart failure and 12.5 mg once daily in patients with more severe heart failure. The dosage may be increased at weekly (or longer) intervals until optimum blood pressure reduction is achieved. If treatment is to be discontinued, the dosage should be reduced gradually over a period of 1-2 weeks. IV Injection- Arrhythmias: By intravenous injection, up to 5 mg at a rate of 1-2 mg/minute, repeated after 5 minutes if necessary, total dose 10-15 mg. In surgery: By slow intravenous injection 2-4 mg at induction or to control arrhythmias developing during anaesthesia; 2 mg doses may be repeated to a maximum of 10 mg. Myocardial Infarction: Early intervention within 12 hours of infarction, by intravenous injection 5 mg every 2 minutes to a maximum of 15 mg, followed after 15 minutes by 50 mg by mouth every 6 hours for 48 hours; maintenance 200 mg daily in divided doses. Interaction of Betaloc 25 mgCatecholamine?depleting drugs (e.g. Reserpine, Monoamine Oxidase (MAO) inhibitors) may have an additive effect when given with beta?blocking agents. Drugs that inhibit CYP2D6 such as quinidine, fluoxetine, paroxetine and propafenone are likely to increase Metoprolol concentration. These increases in plasma concentration would decrease the cardioselectivity of Metoprolol. Concomitant use of digitalis glycosides and beta?blockers can increase the risk of bradycardia. Beta?blockers may exacerbate the rebound hypertension which can follow the withdrawal of clonidine.ContraindicationsAV block, Uncontrolled heart failure, severe bradycardia, sick-sinus syndrome, cardiogenic shock and severe peripheral arterial disease. Known hypersensitivity to Metoprolol or other B-blockers. Metoprolol is also contra-indicated when myocardial infarction is complicated by significant bradycardia, first-degree heart block, systolic hypotension (<100mmHg) and/or severe heart failure.Side Effects of Betaloc 25 mgTiredness, dizziness, depression, diarrhea, itching or rash, shortness of breath, slow heart rate, mental confusion, headache, somnolence, nightmares, insomnia, dyspnea, Nausea, dry mouth, gastric pain, constipation, flatulence, digestive tract disorders, heartburn, pruritus, musculoskeletal pain, blurred vision, decreased libido, and tinnitus have also?been?reported,?intensification?of?AV?block.Pregnancy & LactationMetoprolol should not be used in pregnancy or lactating mothers?unless the physician considers that the benefit outweighs the possible hazard to the?fetus or infant.Precautions & WarningsBronchospastic Diseases: Because of its relative beta 1 ?selectivity, however, Metoprolol may be used with caution in patients with bronchospastic disease who do not respond to, or cannot tolerate other antihypertensive treatment. Major Surgery: The necessity or desirability of withdrawing beta?blocking therapy prior to major surgery is controversial; the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures. Diabetes and Hypoglycemia: Beta?blockers may mask tachycardia occurring with hypoglycemia, but other manifestations such as dizziness and sweating may not be significantly affected. Peripheral Vascular Disease: Beta?blockers can precipitate or aggravate symptoms of arterial insufficiency in patients with peripheral vascular disease. Calcium Channel Blockers: Because of significant inotropic and chronotropic effects in patients, caution should be exercised in patients treated with these agents concomitantly.Overdose Effects of Betaloc 25 mgPoisoning due to an overdose of metoprolol may lead to severe hypotension, sinus?bradycardia, atrioventricular block, heart failure, cardiogenic shock, cardiac arrest,?bronchospasm, impairment of consciousness, coma, nausea, vomiting, cyanosis, hypoglycaemia and, occasionally, hyperkalaemia. The first manifestations usually appear 20 minutes to 2 hours?after drug ingestion. Treatment: Treatment should include close monitoring of cardiovascular,?respiratory and renal function, and blood glucose and electrolytes. Further absorption may be?prevented by induction of vomiting, gastric lavage or administration of activated-charcoal if?ingestion is recent. Cardiovascular complications should be treated symptomatically, which may?require the use of sympathomimetic agents (e.g. noradrenaline, metaramionl), atropine or?inotropic agents (e.g. dopamine, dobutamine). Temporary pacing may be required for AV block.?Glucagon can reverse the effects of excessive B-blockade, given in a dose of 1-10 mg?intravenously. Intravenous B2-stimulants e.g. terbutaline may be required to relieve?bronchospasm. Metoprolol cannot be effectively removed by haemodialysis.Storage ConditionsStore in a cool and dry place, protected from light.Use In Special PopulationsRenal Impairment: No dosage adjustment needed.Hepatic Impairment: Reduce dose.Mode Of ActionMetoprolol is a selective beta1-blocker. Metoprolol reduces or inhibits the agonistic effect on the heart of catecholamines (which are released during physical and mental stress). This means that the usual increase in heart rate, cardiac output, cardiac contractility and blood pressure, produced by the acute increase in catecholamines, is reduced by Metoprolol. Metoprolol interferes less with Insulin release and carbohydrate metabolism than do non-selective beta-blockers. Metoprolol interferes much less with the cardiovascular response to hypoglycaemia than do non-selective beta-blockers.PregnancyPregnancy Category C. There are no adequate and well?controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Metoprolol is excreted in breast milk in very small quantities. Caution should be exercised when Metoprolol is administered to a nursing woman.Pediatric UsesHepatic impaired patient: Metoprolol should be used with caution in patients with impaired hepatic function. Pediatric Use: No clinically relevant differences in the adverse event profile were observed for pediatric patients aged 6 to 16 years as compared with adult patients. Safety and effectiveness of Metoprolol have not been established in patients <6 years of age. Geriatric Use: There were no notable differences in efficacy or the rate of adverse events between older and younger patients.Sku: 1736107992-4615
Betaloc25 mg
₦1,193.50Original price was: ₦1,193.50.₦1,074.15Current price is: ₦1,074.15.₦1,193.50Original price was: ₦1,193.50.₦1,074.15Current price is: ₦1,074.15. Add to basket Quick View -
SaleVigorex 50 mgSildenafil is indicated for the treatment of erectile dysfunction and pulmonary arterial hypertension.Theropeutic ClassDrugs for Erectile DysfunctionPharmacologySildenafil is a selective inhibitor of cyclic Guanosine Monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) used for treatment of erectile dysfunction. Danafil (Sildenafil) enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum that results in smooth muscle relaxation and inflow of blood to the corpus cavernosum.Dosage of Vigorex 50 mgErectile dysfunction: For most patients, the recommended dose is 50 mg taken, as needed, approximately 1 hour before sexual activity. However, Sildenafil may be taken anywhere from 4 hours to 0.5 hour before sexual activity. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. The maximum recommended dosing frequency is once per day.The following factors are associated with increased plasma levels of Sildenafil: age >65, hepatic impairment, severe renal impairment, and concomitant use of potent cytochrome P450 3A4 inhibitors (ketoconazole, itraconazole, erythromycin, saquinavir). Since higher plasma levels may increase both the efficacy and incidence of adverse events, a starting dose of 25 mg should be considered in these patients. Sildenafil was shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors or nitrates in any form is therefore contraindicated. When Sildenafil is co-administered with an alpha-blocker, patients should be stable on alphablocker therapy prior to initiating Sildenafil treatment and Sildenafil should be initiated at the lowest dose.Pulmonary arterial hypertension: The recommended dose of Vigorex 50 mg is 20 mg three times a day and should be taken approximately 4-6 hours apart, with or without food.Administration of Vigorex 50 mgSildenafil?may takes longer time to work if you take it with a heavy meal.Interaction of Vigorex 50 mgSildenafil metabolism is principally mediated by the cytochrome P450 (CYP) isoforms 3A4 (major route) and 2C9 (minor route). Therefore, inhibitors of these isoenzymes 15 may reduce Sildenafil clearance and inducers of these isoenzymes may increase Sildenafil clearance. Cimetidine (800 mg), a nonspecific CYP inhibitor, caused a 56% increase in plasma Sildenafil concentrations when coadministered with Sildenafil (50 mg) to healthy volunteers. When a single 100 mg dose of Sildenafil was administered with erythromycin, a specific CYP3A4 inhibitor, at steady state (500 mg bid for 5 days), there was a 182% increase in Sildenafil systemic exposure (AUC). In addition, in a study performed in healthy male volunteers, co-administration of the HIV protease inhibitor saquinavir, also a CYP3A4 inhibitor, at steady state (1200 mg tid) with Sildenafil (100 mg single dose) resulted in a 140% increase in Sildenafil Cmax and a 210% increase in Sildenafil AUC. Sildenafil had no effect on saquinavir pharmacokinetics. Stronger CYP3A4 inhibitors such as ketoconazole or itraconazole would be expected to have still greater effects, and population data from patients in clinical trials did indicate a reduction in Sildenafil clearance when it was coadministered with CYP3A4 inhibitors (such as ketoconazole, erythromycin, or cimetidine). In another study in healthy male volunteers, coadministration with the HIV protease inhibitor ritonavir, which is a highly potent P450 inhibitor, at steady state (500 mg bid) with Sildenafil (100 mg single dose) resulted in a 300% (4-fold) increase in Sildenafil Cmax and a 1000% (11-fold) increase in Sildenafil plasma AUC. At 24 hours the plasma levels of Sildenafil were still approximately 200 ng/mL, compared to approximately 5 ng/mL when Sildenafil was dosed alone. This is consistent with ritonavir's marked effects on a broad range of P450 substrates. Sildenafil had no effect on ritonavir pharmacokinetics. Although the interaction between other protease inhibitors and Sildenafil has not been studied, their concomitant use is expected to increase Sildenafil levels. In a study of healthy male volunteers, co-administration of Sildenafil at steady state (80 mg t.i.d.) with endothelin receptor antagonist bosentan (a moderate inducer of CYP3A4, CYP2C9 and possibly of cytochrome P450 2C19) at steady state (125 mg b.i.d.) resulted in a 63% decrease of Sildenafil AUC and a 55% decrease in Sildenafil Cmax. Concomitant administration of strong CYP3A4 inducers, such as rifampin, is expected to cause greater decreases in plasma levels of Sildenafil. Single doses of antacid (magnesium hydroxide/aluminum hydroxide) did not affect the bioavailability of Sildenafil. Pharmacokinetic data from patients in clinical trials showed no effect on Sildenafil pharmacokinetics of CYP2C9 inhibitors (such as tolbutamide, warfarin), CYP2D6 inhibitors (such as selective serotonin reuptake inhibitors, tricyclic antidepressants), thiazide and related diuretics, ACE inhibitors, and calcium channel blockers. The AUC of the active metabolite, N-desmethyl Sildenafil, was increased 62% by loop and potassium-sparing diuretics and 102% by 16 nonspecific beta-blockers. These effects on the metabolite are not expected to be of clinical consequence.ContraindicationsSildenafil is contraindicated in patient with hypersensitivity to any component of this medication. Sildenafil potentiates the hypotensive effects of nitrates, so it is contraindicated in patients who are using organic nitrates, either regularly or intermittently.Side Effects of Vigorex 50 mgBody as a whole: face edema, photosensitivity reaction, shock, asthenia, pain, chills, accidental fall, abdominal pain, allergic reaction, chest pain, accidental injury.Cardiovascular: angina pectoris, AV block, migraine, syncope, tachycardia, palpitation,hypotension, postural hypotension, myocardial ischemia, cerebral thrombosis, cardiac arrest, heart failure, abnormal electrocardiogram, cardiomyopathy.Digestive: vomiting, glossitis, colitis, dysphagia, gastritis, gastroenteritis, esophagitis, stomatitis, dry mouth, liver function tests abnormal, rectal hemorrhage, gingivitis.Hemic and Lymphatic: anemia and leukopenia.Metabolic and Nutritional: thirst, edema, gout, unstable diabetes, hyperglycemia, peripheral edema, hyperuricemia, hypoglycemic reaction, hypernatremia.Musculoskeletal: arthritis, arthrosis, myalgia, tendon rupture, tenosynovitis, bone pain,myasthenia, synovitis.Nervous: ataxia, hypertonia, neuralgia, neuropathy, paresthesia, tremor, vertigo, depression, insomnia, somnolence, abnormal dreams, reflexes decreased, hyperesthesia.Respiratory: asthma, dyspnea, laryngitis, pharyngitis, sinusitis, bronchitis, sputum increased, cough increased.Skin and Appendages: urticaria, herpes simplex, pruritus, sweating, skin ulcer, contact dermatitis, exfoliative dermatitis.Special Senses: sudden decrease or loss of hearing, mydriasis, conjunctivitis, photophobia, tinnitus, eye pain, ear pain, eye hemorrhage, cataract, dry eyes.Urogenital: cystitis, nocturia, urinary frequency, breast enlargement, urinary incontinence, abnormal ejaculation, genital edema and anorgasmia.Cardiovascular and cerebrovascular: Serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, subarachnoid and intracerebral hemorrhages, and pulmonary hemorrhage have been reported post-marketing in temporal association with the use of Sildenafil. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of Sildenafil without sexual activity. Others were reported to have occurred hours to days after the use of Sildenafil and sexual activity. It is not possible to determine whether these events are related directly to Sildenafil, to sexual activity, to the patient's underlying 23 cardiovascular disease, to a combination of these factors, or to other factors.Nervous: seizure, seizure recurrence, anxiety, and transient global amnesia.Urogenital: prolonged erection, priapism and hematuria.Special Senses: diplopia, temporary vision loss/decreased vision, ocular redness or bloodshot appearance, ocular burning, ocular swelling/pressure, increased intraocular pressure, retinal vascular disease or bleeding, vitreous detachment/traction, paramacular edema and epistaxis.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies of Sildenafil in pregnant women. Sildenafil is not indicated for use by women. In animal study shows that Sildenafil has no evidence of teratogenicity or embryotoxicity.Precautions & WarningsGeneral: The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment.Before prescribing Sildenafil, it is important to note the following: Caution is advised when Phosphodiesterase Type 5 (PDE5) inhibitors are co-administered with alpha-blockers. PDE5 inhibitors, including Sildenafil, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. In some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (e.g. dizziness, lightheadedness, fainting).Consideration should be given to the following: Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor. Patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors. In those patients who are stable on alpha-blocker therapy, PDE5 inhibitors should be initiated at the lowest dose. In those patients already taking an optimized dose of a PDE5 inhibitor, alpha-blocker therapy should be initiated at the lowest dose. A stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure when taking a PDE5 inhibitor. Safety of combined use of PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs. Sildenafil has systemic vasodilatory properties and may augment the blood pressure-lowering effect of other anti-hypertensive medications. Patients on multiple antihypertensive medications were included in the pivotal clinical trials for Sildenafil. In a separate drug interaction study, when amlodipine, 5 mg or 10 mg, and Sildenafil, 100 mg were orally administered concomitantly to hypertensive patients mean additional blood pressure reduction of 8 mmHg systolic and 7 mmHg diastolic were noted. The safety of Sildenafil is unknown in patients with bleeding disorders and patients with active peptic ulceration. Sildenafil should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). The safety and efficacy of combinations of Sildenafil with other treatments for erectile dysfunction have not been studied. Therefore, the use of such combinations is not recommended. There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease. Therefore, treatments for erectile dysfunction, including Sildenafil, should not be generally used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. Sildenafil has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg). While this normally would be expected to be of little consequence in most patients, prior to prescribing Sildenafil, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity.Patients with the following underlying conditions can be particularly sensitive to the actions of vasodilators including Sildenafil - those with left ventricular outflow obstruction (e.g. aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure.There is no controlled clinical data on the safety or efficacy of Sildenafil in the following groups; if prescribed, this should be done with caution. Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; Patients with resting hypotension (BP 170/110); Patients with cardiac failure or coronary artery disease causing unstable angina; Patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); Patients with sickle cell or related anemias. Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported infrequently since market approval of Sildenafil. In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency could result. If Sildenafil is prescribed to patients taking ritonavir, caution should be used. Data from subjects exposed to high systemic levels of Sildenafil are limited. Visual disturbances occurred more commonly at higher levels of Sildenafil exposure. Decreased blood pressure, syncope, and prolonged erection were reported in some healthy volunteers exposed to high doses of Sildenafil (200-800 mg). To decrease the chance of adverse events in patients taking ritonavir, a decrease in Sildenafil dosage is recommended.Overdose Effects of Vigorex 50 mgIn studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but incidence rates and severities were increased. 24 In cases of overdose, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as Sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.Storage ConditionsKeep in a dry place, away from light and heat. Keep out of the reach of children.Drug ClassesDrugs for Erectile DysfunctionMode Of ActionMechanism of Action: The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation. NO then activates the enzyme guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP), producing smooth muscle relaxation in the corpus cavernosum and allowing inflow of blood. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum, but enhances the effect of nitric oxide (NO) by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. When sexual stimulation causes local release of NO, inhibition of PDE5 by Sildenafil causes increased levels of cGMP in the corpus cavernosum, resulting in smooth muscle relaxation and inflow of blood to the corpus cavernosum. Sildenafil at recommended doses has no effect in the absence of sexual stimulation.Pharmacokinetics and Metabolism: Sildenafil is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (range 25-63%). It is eliminated predominantly by hepatic metabolism (mainly cytochrome P450 3A4) and is converted to an active metabolite with properties similar to the parent, Sildenafil. Both Sildenafil and the metabolite have terminal half lives of about 4 hours.Absorption and Distribution: Sildenafil is rapidly absorbed. Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When Sildenafil is taken with a high fat meal, the rate of absorption is reduced.Metabolism and Excretion: Sildenafil is cleared by hepatic microsomal isoenzymes. After either oral or intravenous administration, Sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).Pharmacokinetics in Special Populations: Geriatrics: Healthy elderly volunteers (65 years or over) had a reduced clearance of Sildenafil, resulting in approximately 84% and 107% higher plasma AUC values of Sildenafil compared to those seen in healthy younger volunteers.PregnancyPregnancy category B. There are no adequate and well-controlled studies of Sildenafil in pregnant women. Sildenafil is not indicated for use by women. In animal study shows that Sildenafil has no evidence of teratogenicity or embryotoxicity.Sku: 1736107986-4614
Vigorex50 mg
₦1,655.50Original price was: ₦1,655.50.₦1,489.95Current price is: ₦1,489.95.₦1,655.50Original price was: ₦1,655.50.₦1,489.95Current price is: ₦1,489.95. Add to basket Quick View -
SaleOsartil Plus 50 mg+12.5 mgThis is indicated for the treatment of hypertension. It is also indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.Theropeutic ClassCombined antihypertensive preparationsPharmacologyLosartan is an angiotensin II receptor antagonist. It selectively and competitively blocks the vasoconstricting and aldosterone-secreting effects of angiotensin II by selectively antagonising its binding to AT1 receptors.Hydrochlorothiazide inhibits the reabsorption of Na in the distal tubules causing increased excretion of Na and water including K and hydrogen ions.Dosage & Administration of Osartil Plus 50 mg+12.5 mgHypertension: Usual starting dose: 50/12.5 mg once daily. Titrate as needed to a maximum dose of 100/25 mg. Hypertensive Patients with Left Ventricular Hypertrophy: Not controlled on monotherapy: Initiate with 50/12.5 mg. Titrate as needed to a maximum of 100/25 mg. Dosing must be individualised. The usual starting dose of Losartan is 50 mg once daily, with 25 mg recommended for patients with intravascular volume depletion (e.g., patients treated with diuretics) and patients with a history of hepatic impairment. Losartan can be administered once or twice daily at total daily doses of 25 to 100 mg. If the antihypertensive effect measured trough using once a day dosing is inadequate, a twice a day regimen at the same total daily dose or an increase in dose may give a more satisfactory response. Hydrochlorothiazide is effective in doses of 12.5 to 50 mg once daily and can be given at doses of 12.5 to 25 mg. To minimise dose independent side effects, it is usually appropriate to begin combination therapy only after a patient has failed to achieve the desired effect with monotherapyDosage of Osartil Plus 50 mg+12.5 mgHypertension- The usual starting dose of 50/12.5 is one tablet once daily. For patients who do not respond adequately to one tablet the dosage may be increased to 100/25 once daily. A patient whose blood pressure is not adequately controlled with Losartan 100 mg monotherapy may be switched to this combination 100/12.5 once daily. In hypertensive patients with left ventricular hypertrophy initial dose is 50/12.5, if additional blood pressure reduction is needed, 100/12.5 may be given, followed by 100/25 if required. The maximum dose is 100/25 once daily. In general, the antihypertensive effect is attained within three weeks after initiation of therapy. No initial dosage adjustment of 50/12.5 is necessary for elderly patients. But maximum dose of 100/25 once daily dose should not be used as initial therapy in elderly patients. Severe Hypertension: The starting dose for initial treatment of severe hypertension is one tablet of 50/12.5 once daily. For patients who do not respond adequately to this dose after 2 to 4 weeks of therapy, the dosage may be increased to 100/25 once daily. The maximum dose is one tablet of 100/25 once daily. Administration of Osartil Plus 50 mg+12.5 mgThis preparation may be administered with other antihypertensive agents. This may be administered with or without food.Interaction of Osartil Plus 50 mg+12.5 mgLosartan Potassium: No significant drug-drug pharmacokinetic interactions have been found in interaction studies with Hydrochlorothiazide, Digoxin, Warfarin, Cimetidine and Phenobarbital. As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g. Spironolactone, Triamterene, Amiloride), potassium supplements, or salt substitutes containing potassium may lead to increase in serum potassium. As with other antihypertensive agents, the antihypertensive effect of Losartan may be blunted by the non-steroidal anti-inflammatory drug Indomethacin.Hydrochlorothiazide: When administered concurrently, the following drugs may interact with Thiazide diuretics: alcohol, barbiturates, or narcotics-potentiation of orthostatic hypotension may occur. Antidiabetic drugs (oral agents and Insulin): dosage adjustment of the antidiabetic drug may be required.Other antihypertensive drugs: additive effect or potentiation.Cholestyramine and colestipol resins: absorption of Hydrochlorothiazide is impaired in the presence of anionic exchange resinsContraindicationsThe combination of Losartan and Hydrochlorothiazide is contraindicated in patients who are hypersensitive to any component of this product. Because of the Hydrochlorothiazide component, this product is contraindicated in patients with anuria or hypersensitivity to other sulfonamide-derived drugs.Side Effects of Osartil Plus 50 mg+12.5 mgSide-effects are usually mild. Symptomatic hypotension including dizziness may occur, particularly in patients with intravascular volume depletion (e.g. those taking high-dose diuretics). Hyperkalaemia occurs occasionally; angioedema has also been reported with some angiotensin-II receptor antagonists. Vertigo; less commonly gastro-intestinal disturbances, angina, palpitation, oedema, dyspnoea, headache, sleep disorders, malaise, urticaria, pruritus, rash; rarely hepatitis, atrial fibrillation, cerebrovascular accident, syncope, paraesthesia; also reported pancreatitis, anaphylaxis, cough, depression, erectile dysfunction, anaemia, thrombocytopenia, hyponatraemia, arthralgia, myalgia, renal impairment, rhabdomyolysis, tinnitus, photosensitivity, and vasculitis (including Henoch-Schonlein purpura)Pregnancy & LactationWhen pregnancy is detected, Losartan & Hydrochlorothiazide?should be discontinued as soon as possible. It is not known whether Losartan is excreted in human milk. Thiazides appear in human milk. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.Precautions & Warnings Hypersensitivity: Angiooedema Periodic determination of serum electrolytes to detect possible electrolyte imbalance should be performed at appropriate intervals Hypokalemia may rarely develop, especially with brisk diuresis, when severe cirrhosis is present, or after prolonged therapy Impaired renal function and Symptomatic hypotension Overdose Effects of Osartil Plus 50 mg+12.5 mgLosartan Potassium: Limited data are available in regard to overdosage in humans. The most likely manifestation of overdosage would be hypotension and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. If symptomatic hypotension should occur, supportive treatment should be instituted. Neither losartan nor its metabolite can be removed by hemodialysis.Hydrochlorothiazide: The most common signs and symptoms observed are those caused by electrolyte depletion (hypokalemia, hypochloremia, and dehydration resulting from excessive diuresis. If digitalis has also been administered, hypokalemia, may accentuate cardiac arrhythmias. The degree to which Hydrochlorothiazide is removed by hemodialysis has not been established.Storage ConditionsDo not store above 30?C. Keep out of the reach of children.Use In Special PopulationsUse in pediatric patients: The safety and effectiveness in paediatric patients have not been established.Use in patients with renal impairment: The usual regimens of therapy with Losartan & Hydrochlorothiazide may be followed as long as the patient?s creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so Losartan & Hydrochlorothiazide is not recommended.Patients with hepatic impairment: Losartan & Hydrochlorothiazide is not recommended for titration in patients with hepatic impairment because the appropriate 25 mg starting dose of losartan cannot be given.Drug ClassesCombined antihypertensive preparationsMode Of ActionAngiotensin II formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE), is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues, (e.g. vascular smooth muscle, adrenal gland). In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT1 receptor. Neither Losartan nor its active metabolite inhibits ACE (kinase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin); nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.Hydrochlorothiazide is a thiazide diuretic. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of Sodium and Chloride in approximately equivalent amounts. Indirectly, the diuretic action of Hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in Aldosterone secretion, increases in urinary Potassium loss, and decreases in serum Potassium. The renin-aldosterone link is mediated by angiotensin II, so co-administration of an angiotensin II receptor antagonist tends to reverse the Potassium loss associated with these diuretics.PregnancyAngiotensin-II receptor antagonists should be avoided in pregnancy unless essential. They may adversely affect fetal and neonatal blood pressure control and renal function; skull defects and oligohy dramnios have also been reported. Information on the use of angiotensin-II receptor antagonists in breastfeeding is limited. They are not recommended in breastfeeding and alternative treatment options, with better-established?safety information during breastfeeding, are available.Pediatric UsesUse in Patients with Renal Impairment: The usual regimens of therapy with 50/12.5 may be followed as long as the patient's creatinine clearance is >30 ml/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides. In that case, hydrochlorothiazide is not recommended.Use in Patients with Hepatic Impairment: The combination of Losartan and Hydrochlorothiazide is not recommended for titration in patients with hepatic impairment because the appropriate 25 mg starting dose of Losartan cannot be given.Use in pediatric patients: The safety and effectiveness in pediatric patients have not been established.Sku: 1736107983-4613
Osartil Plus50 mg+12.5 mg
₦5,500.00Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00.₦5,500.00Original price was: ₦5,500.00.₦4,950.00Current price is: ₦4,950.00. Add to basket Quick View -
SalePregaba 50 mgPregaba 50 mg is indicated for: Neuropathic pain linked to diabetic peripheral neuropathy is one condition for which Pregaba 50 mg is prescribed (DPN) Neuralgia following shingles (PHN) Treatment of partial-onset seizures in patients older than one month with adjunctive therapy Fibromyalgia neuropathic pain brought on by spinal cord damage. Neuropathic pain linked to diabetic peripheral neuropathy is one condition for which Pregaba 50 mg is prescribed (DPN) Neuralgia following shingles (PHN) Treatment of partial-onset seizures in patients older than one month with adjunctive therapy Fibromyalgia the neuropathic pain brought on by spinal cord damage The following conditions are treated with Pregaba 50 mg CR tablets: Neuropathic pain brought on by diabetic peripheral neuropathy (DPN) Neuralgia following shingles (PHN)Theropeutic ClassSupplemental antiepileptic medicationsPharmacologyGamma-amino butyric acid, an inhibitory neurotransmitter, is the structural basis of the drug Pregaba 50 mg (GABA). The GABAA, GABAB, or benzodiazepine receptors are not directly bound by it. In the tissues of the central nervous system, Pregaba 50 mg binds to the alpha-2-delta site (an auxiliary subunit of voltage-gated calcium channels) with a high affinity. Pregaba 50 mg has a 90% oral bioavailability that is dose-independent. In people with normal renal function, it is largely excreted from the body through the kidneys as an unaltered medication with a mean elimination half-life of 6.3 hours.Dosage & Administration of Pregaba 50 mgNeuropathic pain associated with diabetic peripheral neuropathy: The maximum recommended dose of Pregaba 50 mg is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability.Post-herpetic neuralgia: The recommended dose of Pregaba 50 mg is 75 to 150 mg two times a day, or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 mL/min. Dosing should begin at 75 mg two times a day, or 50 mg three times a day (150 mg/day) and may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Adjunctive therapy for adult patients with partial onset seizures: In general, it is recommended that patients be started on a total daily dose no greater than 150 mg/day (75 mg two times a day, or 50 mg three times a day). Based on individual patient response and tolerability, the dose may be increased to a maximum dose of 600 mg/day.Management of Fibromyalgia: The recommended dose of Pregaba 50 mg for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability.Neuropathic pain associated with spinal cord injury: The recommended dose range is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Pregaba 50 mg capsules can be taken without regards to meals.Dosage of Pregaba 50 mgNeuropathic pain associated with diabetic peripheral neuropathy in adults (DPN): The maximum recommended dose of Pregaba 50 mg is 100 mg three times a day (300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Begin dosing of Pregaba 50 mg CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. The maximum recommended dose of Pregaba 50 mg CR capsule is 330 mg once daily.Postherpetic neuralgia in adults (PHN): The recommended dose of Pregaba 50 mg is 75 to 150 mg two times a day or 50 to 100 mg three times a day (150 to 300 mg/day) in patients with creatinine clearance of at least 60 ml/min. Dosing should begin at 75 mg two times a day or 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 300 mg/day and who are able to tolerate Pregaba 50 mg, may be treated with up to 300 mg two times a day or 200 mg three times a day (600 mg/day).Begin dosing of Pregaba 50 mg CR capsule at 165 mg once daily and increase to 330 mg once daily within 1 week based on individual patient response and tolerability. Patients who do not experience sufficient pain relief following 2 to 4 weeks of treatment with 330 mg once daily and who are able to tolerate Pregaba 50 mg CR capsule, may be treated with up to 660 mg once daily. In view of the dose-dependent adverse reactions and the higher rate of treatment discontinuation due to adverse reactions, dosing above 330 mg/day should be reserved only for those patients who have on-going pain and are tolerating 330 mg daily. The maximum recommended dose of Pregaba 50 mg CR capsule is 660 mg once daily.Management of fibromyalgia in adults: The recommended dose of Pregaba 50 mg is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day).Neuropathic pain associated with spinal cord injury in adults: The recommended dose range of Pregaba 50 mg is 150 to 600 mg/day. The recommended starting dose is 75 mg two times a day (150 mg/day). The dose may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Patients who do not experience sufficient pain relief after 2 to 3 weeks of treatment with 150 mg two times a day and who tolerate Pregaba 50 mg may be treated with up to 300 mg two times a day. Conversion from Pregaba 50 mg capsules to Pregaba 50 mg CR capsule tablet: When switching from Pregaba 50 mg capsules to Pregaba 50 mg CR capsule tablet on the day of the switch, instruct patients to take their morning dose of Pregaba 50 mg capsule as prescribed and initiate Pregaba 50 mg CR capsule therapy after an evening meal.Pregaba 50 mg tablet total daily dose (dosed 2 or 3 times daily): Pregaba 50 mg CR capsule capsule dose (dosed once a day) 75 mg/daily: 82.5 mg/day 150 mg/daily: 165 mg/day 225 mg/daily: 247.5 mg/day 300 mg/daily: 330 mg/day 450 mg/daily: 495 mg/day 600 mg/daily: 660 mg/dayAdministration of Pregaba 50 mgRoute of administration: Pregaba 50 mg is administered orally. Taking it with or without food is acceptable. The Pregaba 50 mg CR tablet should be taken after dinner. It shouldn't be divided, crushed, or chewed; it should be consumed whole. Patients should take their regular dose of Pregaba 50 mg CR after a snack if they forget to take their evening mealtime dose of Pregaba 50 mg CR. If they forget to take Pregaba 50 mg CR before going to bed, they should take their regular dose of Pregaba 50 mg CR after breakfast. They should take their regular dose of Pregaba 50 mg CR at the regular time that evening after an evening meal if they forget to take their daily dose of Pregaba 50 mg CR after the morning meal.Interaction of Pregaba 50 mgDrug interaction with medication: There are not anticipated to be many significant pharmacokinetic medication interactions involving Pregaba 50 mg. No relevant drug-food or other-drug interactions.ContraindicationsThose with a known hypersensitivity to Pregaba 50 mg or any of its ingredients should not take Pregaba 50 mg.Side Effects of Pregaba 50 mgDizziness, somnolence, dry mouth, edema, impaired vision, weight gain, and aberrant thinking (mainly difficulties with concentration/attention) are the most frequent adverse effects in adults. Increased weight and increased hunger are the most frequent adverse reactions in children receiving therapy for partial-onset seizures.Pregnancy & LactationPregaba 50 mg is classified as a C pregnancy drug. Hence, it should only be used if the potential benefits outweigh the hazards to the fetus. Pregaba 50 mg should only be administered to nursing mothers if the risks are clearly outweighed by the potential benefits. Pregaba 50 mg may be released through breast milk like other medications.Precautions & WarningsAngioedema (swelling of the throat, head, and neck, for example) can happen and is sometimes linked to respiratory compromise that requires immediate medical attention. In these circumstances, Pregaba 50 mg should be stopped promptly. Also, if hypersensitivity reactions like hives, dyspnea, or wheezing manifest, Pregaba 50 mg should be stopped right away. Pregaba 50 mg and other antiepileptic medications raise the chance of having suicidal ideas or actions. Pregaba 50 mg may cause respiratory depression when used concurrently with CNS depressants or when there is underlying respiratory impairment. Patients must be watched closely, and dosage needs to be modified as necessary. Pregaba 50 mg may make a patient drowsy and woozy, making it difficult for them to drive or operate machinery. Pregaba 50 mg may become more frequent in seizures or have other negative effects if it is abruptly stopped. Pregaba 50 mg should be discontinued gradually over at least two weeks.Overdose Effects of Pregaba 50 mgReduced consciousness, melancholy or anxiety, confusional mood, agitation, and restlessness are signs and symptoms of a Pregaba 50 mg overdose. As well as heart block and seizures, there have been reports. There isn't a particular remedy. If necessary, emesis or stomach lavage may be used to try to eliminate any unabsorbed medication; normal safety procedures should be followed to preserve the airway. It is necessary to provide the patient with general supportive care, which includes keeping track of their vital signs and assessing their clinical condition.Storage ConditionsMaintain in a cool, dry location (below 30?C), away from light and moisture. Keep out of children's reach.Use In Special PopulationsPregaba 50 mg's efficacy and safety in pediatric patients have not been shown.Drug ClassesAdjunct anti-epileptic drugs, Primary anti-epileptic drugsMode Of ActionGamma-aminobutyric acid, an inhibitory neurotransmitter, is the structural basis of the drug Pregaba 50 mg (GABA). It doesn't directly bind to benzodiazepine, GABAA, or GABAB receptors. In the tissues of the central nervous system, Pregaba 50 mg binds to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) with a high affinity. Pregaba 50 mg's mechanism of action is still unknown, although findings from animal research point to a potential role for binding to the alpha2-delta subunit in the drug's anti-nociceptive and anti-seizure properties.PregnancyPregaba 50 mg use in expectant women has not been adequately and carefully studied. The potential harm to a fetus should be disclosed to expectant mothers. Pregaba 50 mg has been found in trace levels in the milk of nursing women. Breastfeeding is not advised while using Pregaba 50 mg due to the potential risk of tumorigenicity.Pediatric UsesUsage in children and adolescents: Safety and efficacy for the treatment of fibromyalgia, postherpetic neuralgia, neuropathic pain associated with spinal cord injury, and neuropathic pain associated with diabetic peripheral neuropathy in pediatric patients have not been proven. The safety and efficacy of supplementary therapy for partial onset seizures in pediatric children younger than one month of age have not been established. Pregaba 50 mg extended-release tablet safety and efficacy in pediatric patients have not been shown.Sku: 1736107980-4612
Pregaba50 mg
₦825.00Original price was: ₦825.00.₦742.50Current price is: ₦742.50. -
SaleFebus 40 mgFebus 40 mg is indicated for the chronic management of hyperuricemia in patients with gout. Febus 40 mg is not recommended for the treatment of asymptomatic hyperuricemia.Theropeutic ClassDrugs used in GoutPharmacologyFebus 40 mg is a non-purine, selective xanthine oxidase (XO) inhibitor. It decreases serum uric acid level by inhibiting xanthine oxidase, which is responsible for uric acid production. Xanthine oxidase breaks down hypoxanthine to xanthine and thus to uric acid. Febus 40 mg is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.Dosage & Administration of Febus 40 mgFebus 40 mg is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Febus 40 mg is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, Febus 40 mg 80 mg is recommended. Febus 40 mg can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febus 40 mg to patients with mild to moderate renal or hepatic impairment.Dosage of Febus 40 mgFebus 40 mg is recommended at 40 mg or 80 mg once daily. The recommended starting dose of Febus 40 mg is 40 mg once daily. For patients who do not achieve a serum uric acid less than 6 mg /dL after 2 weeks with 40 mg, Febus 40 mg 80 mg is recommended. Febus 40 mg can be administered without regard to food or antacid use. No dose adjustment is necessary when administering Febus 40 mg to patients with mild to moderate renal or hepatic impairment.Interaction of Febus 40 mgConcomitant administration of Febus 40 mg with azathioprine, mercaptopurine or theophylline could increase plasma concentrations of these drugs resulting in severe toxicity.ContraindicationsFebus 40 mg is contraindicated in patients being treated with azathioprine, mercaptopurine, or theophylline.Side Effects of Febus 40 mgThe most common adverse events associated with the use of Febus 40 mg may include liver function abnormalities, nausea, arthralgia, and rash.Pregnancy & LactationPregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Febus 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Caution should be exercised when Febus 40 mg is administered to a nursing woman.Precautions & WarningsGout Flare: An increase in gout flares is frequently observed during initiation of anti-hyperuricemic agents, including Febus 40 mg. If a gout flare occurs during treatment, Febus 40 mg need not be discontinued. Prophylactic therapy (i.e., non-steroidal anti-inflammatory drug (NSAID) or colchicine upon initiation of treatment) may be beneficial for up to six months.Cardiovascular Events: A higher rate of cardiovascular thromboembolic events was observed in patients treated with Febus 40 mg than allopurinol in clinical trials. Monitor for signs and symptoms of MI and stroke.Liver Enzyme Elevation: Transaminase elevations have been observed in Febus 40 mg -treated patients. Monitor liver function tests periodically.Overdose Effects of Febus 40 mgFebustat was studied in healthy subjects in doses up to 300 mg daily for seven days without evidence of dose-limiting toxicities.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Use In Special PopulationsPediatric Use: Safety and effectiveness in pediatric patients under 18 years of age have not been establishedDrug ClassesDrugs used in GoutMode Of ActionFebus 40 mg is a non-purine, selective xanthine oxidase (XO) inhibitor. It decreases serum uric acid level by inhibiting xanthine oxidase, which is responsible for uric acid production. Xanthine oxidase breaks down hypoxanthine to xanthine and thus to uric acid. Febus 40 mg is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.PregnancyPregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Febus 40 mg should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether this drug is excreted in human milk. Caution should be exercised when Febus 40 mg is administered to a nursing woman.Pediatric UsesPediatric Use: Safety and effectiveness in pediatric patients under 18 years of age have not been establishedSku: 1736107977-4611
Febus40 mg
₦8,250.00Original price was: ₦8,250.00.₦7,425.00Current price is: ₦7,425.00.₦8,250.00Original price was: ₦8,250.00.₦7,425.00Current price is: ₦7,425.00. Add to basket Quick View -
SaleTofen 100 mlTofen 100 ml is indicated in the prophylactic treatment of bronchial asthma, symptomatic treatment of allergic conditions including rhinitis and conjunctivitis.Theropeutic ClassCromoglycate & related drugsPharmacologyTofen 100 ml is a potent anti-allergic substance possessing a powerful and sustained non-competitive histamine (H1) receptor blocking property. It inhibits the release of mediators (e.g histamine, leukotrienes and prostaglandins) from cells responsible for type-(I) allergic reactions. Tofen 100 ml also stabilizes mast cells, decreases chemotaxis, activation of degranulation of eosinophils.??Also, it stabilizes mast cells & basophils and inhibits PAF (platelet activating factor) and is effective in preventing asthmatic attacks.Dosage & Administration of Tofen 100 mlAdults: 1 mg twice daily with food. If necessary the dose may be increased to 2 mg twice daily in severe cases. Children above 2 years: 1 mg twice daily with food. Patient?s known to be easily sedated should begin treatment with 0.5 to 1 mg at night for the first few days or as directed by the physician. Use in elderly: Same as adult dose or as advised by the physician.Interaction of Tofen 100 mlA reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetics and it has been suggested that this combination should therefore be avoided. Since Ketotifen has the properties of the antihistamines, it may potentiate the effects of other CNS depressant drugs such as alcohol, antihistamines, hypnotics and sedatives.ContraindicationsA reversible fall in the platelet count has been observed in a few patients receiving Ketotifen concomitantly with oral antidiabetic agent and it has been suggested that this combination should therefore be avoided.Side Effects of Tofen 100 mlDrowsiness and in isolated cases, dry mouth and slight dizziness may occur at the beginning of treatment, but usually disappear spontaneously after a few days.Pregnancy & LactationAlthough there is no evidence of any teratogenic effect, Ketotifen in pregnancy and lactation is not recommended.Precautions & WarningsTofen 100 ml is important to continue the previous treatment for a minimum of two weeks after starting Ketotifen to avoid the possibility of exacerbation of asthma. This applies specially to systemic corticosteroids and ACTH because of the possible existence of adrenocortical insufficiency in steroid dependent patient. If intercurrent infection occurs, Ketotifen treatment must be supplemented by specific antimicrobial therapy. During the first day of treatment with Ketotifen, reactions may be impaired and patients should be warned not to take charge of vehicle or machinery until the effect of Ketotifen treatment on the individual is known. Patient should be advised to avoid alcoholic drinks. Ketotifen may potentiate the effects of sedatives, hypnotic, antihistamines and alcohol.Overdose Effects of Tofen 100 mlSymptoms: Drowsiness, confusion, dyspnoea, bradycardia or tachycardia, disorientation, convulsions, severe hypotension, reversible coma.Management: Supportive and symptomatic.Storage ConditionsKeep below 30?C temperature, away from light & moisture. Keep out of the reach of children.Sku: 1736107974-4610
Tofen100 ml
₦4,125.00Original price was: ₦4,125.00.₦3,712.50Current price is: ₦3,712.50.₦4,125.00Original price was: ₦4,125.00.₦3,712.50Current price is: ₦3,712.50. Add to basket Quick View -
SaleComet 850 mgTreatment of type 2 diabetes mellitus, particularly in overweight patients when dietary management and exercise alone does not result in adequate glycaemic control. In adults: Metformin may be used as monotherapy or in combination with other oral antidiabetic agents or with insulin. ... Read moreTreatment of type 2 diabetes mellitus, particularly in overweight patients when dietary management and exercise alone does not result in adequate glycaemic control. In adults: Metformin may be used as monotherapy or in combination with other oral antidiabetic agents or with insulin. In children from 10 years of age and adolescents: Metformin may be used as monotherapy or in combination with insulin. A reduction of diabetic complications has been shown in overweight type 2 diabetic adult patients treated with metformin as first-line therapy after diet failure.Theropeutic ClassBiguanidesPharmacologyMetformin is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.Dosage & Administration of Comet 850 mgMetformin immediate release tablet: Dosage of Comet 850 mg must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. Adult: The usual starting dose of Metformin is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. For those patients requiring additional glycemic control, Glucomin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals. Children: The usual starting dose of Metformin is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses. Metformin extended release tablet: Swallow Metformin XR tablet whole and never crush, cut or chew. Adult: The usual starting dose of Metformin XR is 500 mg once daily with the evening meal. Dose should be increased in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal, alternatively increased to 1000 mg twice daily taken with meal. Patient receiving Metformin immediate release tablet may be switched to Metformin extended release tablet up to a maximum recommended daily dose. Children: Metformin extended release tablet has not been studied in children. Renal impaired patient: Do not use Metformin in patients with eGFR below 30 mL/min/1.73 m2. Asses risk/benefit of counting if eGFR falls below 45 mL/min/1.73 m2. Dosage of Comet 850 mgMetformin immediate release tablet: Dosage of Comet 850 mg must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily doses. Adult: The usual starting dose of Metformin is 500 mg twice a day or 850 mg once a day, given with meals. Dosage increases should be made in increments of 500 mg weekly or 850 mg every 2 weeks, up to a total of 2000 mg per day, given in divided doses. For those patients requiring additional glycemic control, Glucomin may be given to a maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given three times a day with meals. Children: The usual starting dose of Metformin is 500 mg twice a day, given with meals. Dosage increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day, given in divided doses. Metformin extended release tablet: Swallow Metformin XR tablet whole and never crush, cut or chew. Adult: The usual starting dose of Metformin XR is 500 mg once daily with the evening meal. Dose should be increased in increments of 500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal, alternatively increased to 1000 mg twice daily taken with meal. Patient receiving Metformin immediate release tablet may be switched to Metformin extended release tablet up to a maximum recommended daily dose. Children: Metformin extended release tablet has not been studied in children. Renal impaired patient: Do not use Metformin in patients with eGFR below 30 mL/min/1.73 m2. Asses risk/benefit of counting if eGFR falls below 45 mL/min/1.73 m2. Interaction of Comet 850 mgCo-administration with Carbonic anhydrase (Topiramate, Zonisamide) may increase risk of lactic acidosis. Drugs (Ranolazine, Dolutegravir, Cimetidine) that reduce Metformin clearance may increase the accumulation of Metformin. Alcohol can potentiate the effect of Metformin on lactate metabolism.Contraindications Hypersensitivity to the active substance or to any of the excipients. Any type of acute metabolic acidosis (such as lactic acidosis, diabetic ketoacidosis). Severe renal failure (GFR <30 mL/min). Acute conditions with the potential to alter renal function such as: dehydration, severe infection, shock. Acute or chronic disease, which may cause tissue hypoxia such as: cardiac or respiratory failure, recent myocardial infarction, shock, Hepatic insufciency, acute alcohol intoxication, alcoholism. Side Effects of Comet 850 mgBlood and lymphatic system disorders: Not known: Hemolytic anemiaMetabolism and nutrition disorders: Very rare: Lactic acidosis. Decrease of vitamin B12 absorption with a decrease of serum levels during long-term use of metformin. Consideration of such etiology is recommended if a patient presents with megaloblastic anemia. Cases of peripheral neuropathy in patients with vitamin B12 deficiency have been reported in post-marketing experience (frequency not known)Nervous system disorders: Common: Taste disturbance. Not known: EncephalopathyGastrointestinal disorders: Very common: Gastrointestinal disorders, such as nausea, vomiting, diarrhea, abdominal pain, and loss of appetite. These undesirable effects occur most frequently during the initiation of therapy and resolve spontaneously in most cases. To prevent them, it is recommended that metformin be taken in 2 or 3 daily doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.Hepatobiliary disorders: Very rare: Isolated reports of liver function test abnormalities or hepatitis resolving upon metformin discontinuation.Skin and subcutaneous tissue disorders: Very rare: Skin reactions, such as erythema, pruritus, urticaria.Pregnancy & LactationPublished studies have not reported a clear association with Metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when Metformin was used during pregnancy.Lactation: Metformin is excreted into human breast milk. No adverse effects were observed in breastfed newborns/infants. However, a decision on whether to discontinue breast-feeding should be made or taking into account the benefit of breast-feeding and the potential risk to adverse effect on the child.Precautions & WarningsComet 850 mg is known to be substantially excreted by the kidney and the risk of Metformin accumulation and lactic acidosis increases with the degree of impairment of renal function. Metformin may lower vitamin B12 level. It also increases risk of hypoglycemia when use in combination with insulin or insulin secretagogue.Overdose Effects of Comet 850 mgHypoglycemia has not been seen with Metformin doses up to 85 gm, although lactic acidosis has occurred in such circumstances. Lactic acidosis is a medical emergency and must be treated in hospital. The most effective method to remove lactate and Metformin is hemodialysis.Storage ConditionsKeep below 30?C temperature, protected from light & moisture. Keep out of the reach of children.Drug ClassesBiguanidesMode Of ActionMetformin is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.PregnancyPregnancy: Uncontrolled diabetes during pregnancy (gestational or permanent) is associated with an increased risk of congenital abnormalities and perinatal mortality. When the patient plans to become pregnant and during pregnancy, it is recommended that diabetes is not treated with metformin but insulin be used to maintain blood glucose levels as close to normal as possible, to reduce the risk of malformations of the foetus.Breastfeeding: Metformin is excreted into human breast milk. No adverse efects were observed in breastfed newborns/infants. However, as only limited data are available, breastfeeding is not recommended during metformin treatment. A decision on whether to discontinue breastfeeding should be made, taking into account the benefit of breastfeeding and the potential risk to adverse effects on the child.Pediatric UsesElderly: Due to the potential for decreased renal function in elderly subjects, the metformin dosage should be adjusted based on renal function. Regular assessment of renal function is necessary.Pediatric population: The diagnosis of type 2 diabetes mellitus should be confirmed before treatment with metformin is initiated. No effect of metformin on growth and puberty has been detected during controlled clinical studies of one-year duration but no long-term data on these specific points are available. Therefore, a careful follow-up of the effect of metformin on these parameters in metformin-treated children, especially prepubescent children, is recommended.Children aged between 10 and 12 years: Particular caution is recommended when prescribing to children aged between 10 and 12 years.Renal function: As metformin is excreted by the kidney, creatinine clearance (this can be estimated from serum creatinine levels by using the Cockcroft-Gault formula) should be determined before initiating treatment and regularly thereafter: At least annually in patients with normal renal function, At least two to four times a year in patients with creatinine clearance at the lower limit of normal and in elderly subjects. Decreased renal function in elderly subjects is frequent and asymptomatic. Special caution should be exercised in situations where renal function may become impaired, for example when initiating antihypertensive therapy or diuretic therapy and when starting therapy with a non-steroidal anti-inflammatory drug (NSAID). GFR should be assessed before treatment initiation and regularly thereafter. Metformin is contraindicate in patients with GFR<30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function.Sku: 1736107971-4609
Comet850 mg
₦3,311.00Original price was: ₦3,311.00.₦2,979.90Current price is: ₦2,979.90.₦3,311.00Original price was: ₦3,311.00.₦2,979.90Current price is: ₦2,979.90. Add to basket Quick View -
SaleAmbrox 100 mlThis is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus ... Read moreThis is indicated in- Productive cough Acute and chronic inflammatory disorders of upper and lower respiratory tracts associated with viscid mucus including acute and chronic bronchitis Inflammatory disease of rhinopharyngeal tract (laryngitis, pharyngitis, sinusitis and rhinitis) associated with viscid mucus Asthmatic bronchitis bronchial asthma with thick expectoration Bronchiectasis Chronic pneumonia etc. Theropeutic ClassCough expectorants & mucolyticsPharmacologyAmbroxol is a metabolite of Bromhexine. It possesses mucokinetic (improvement in mucus transport) and secretolytic (liquefies secretions) properties. Ambroxol stimulates the serous cells of the glands of the mucous membrane of bronchi, increasing the content of mucus secretion. The mucolytic effect is associated with depolymerization and splitting of mucoproteins and mucopolysaccharide fibres, which leads to reduction in the viscosity of mucus. Expectoration of mucus is facilitated and breathing is eased considerably. Ambroxol stimulates production of phospholipids of surfactant by alveolar cells. Ambroxol has anti-inflammatory properties. In patients with COPD, it improves airway patency. Beside these, Ambroxol also exhibits anti oxidant activity. Long-term use is possible because of the good tolerability of the preparation.Dosage & Administration of Ambrox 100 mlAverage daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule:? Adult and children over 12 years old: 1 capsule once daily Specific application features: Ambroxol may be prescribed to patients suffering from diabetes mellitus.Dosage of Ambrox 100 mlAverage daily dose (preferably after meal):Pediatric Drops: 0-6 months: 0.5 ml 2 times a day 6-12 months: 1 ml 2 times a day 1-2 years: 1.25 ml 2 times a day Syrup: 2-5 years: 2.5 ml (1/2 teaspoonful) 2-3 times a day 5-10 years: 5 ml (1 teaspoonful) 2-3 times a day 10 years and adults: 10 ml (2 teaspoonful) 3 times a day. Sustained release capsule: Adult and children over 12 years old: 1 capsule once daily.Interaction of Ambrox 100 mlAmbroxol should not be taken simultaneously with antitussives (e.g.Codeine) because phlegm, which has been liquefied by Ambroxol might not be expectorated.ContraindicationsContraindicated in known hypersensitivity to Ambroxol or Bromhexine.Side Effects of Ambrox 100 mlGastrointestinal side effects like epigastric pain, stomach overfill feeling may occur occasionally. Rarely allergic responses such as eruption, urticaria or angioneurotic edema have been reported.Pregnancy & LactationTeratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use during pregnancy, especially in the 1st trimester. Safety during lactation has not been established.Precautions & WarningsAmbroxol should be given cautiously to patients with gastric and duodenal ulceration or convulsive disorders. Patients with hepatic and renal insufficiency should take it with caution.Storage ConditionsProtect from direct light exposure, Store in a dry place at a temperature not exceeding 30?C, Keep out of the reach of children.Drug ClassesCough expectorants & mucolyticsMode Of ActionAmbroxol is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It improves sputum rheology by hydrating mechanism leading to liquefaction of mucus in the lumen of respiratory tract, thus facilitating expectoration of mucus and reducing dyspnea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Ambroxol has anti inflammatory properties owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites. In patients with COPD it traditionally improves airway patency.PregnancyTeratogenic and fetal toxicity studies have shown no harmful effect of Ambroxol. However, it is advised not to use it in pregnancy, especially during the1st trimester. Safety during lactation has not been established yet.Sku: 1736107968-4608
Ambrox100 ml
₦2,750.00Original price was: ₦2,750.00.₦2,475.00Current price is: ₦2,475.00.₦2,750.00Original price was: ₦2,750.00.₦2,475.00Current price is: ₦2,475.00. Add to basket Quick View -
SaleThyrin 50 mcg As replacement therapy in hypothyroidism of any aetiology. Replacement therapy should not be instituted in transient hypothyroidism during the recovery phase of subacute Thyroiditis. For the suppression of Thyroid Stimulating Hormone (TSH) levels in the presence of goitres, nodules and after radiological and/or surgical treatment of Thyroid cancer. ... Read more As replacement therapy in hypothyroidism of any aetiology. Replacement therapy should not be instituted in transient hypothyroidism during the recovery phase of subacute Thyroiditis. For the suppression of Thyroid Stimulating Hormone (TSH) levels in the presence of goitres, nodules and after radiological and/or surgical treatment of Thyroid cancer. For the suppression of the goitrogenic effects of other drugs such as Lithium. As a diagnostic aid in suppression tests. Theropeutic ClassThyroid drugs & hormonePharmacologyThis tablet contains synthetic Levothyroxine (also called Thyroxine or T4) which is identical to the natural hormone T4, produced in the Thyroid gland. About 30% of T4 is converted to the much more active Triiodothyronine (T3) in peripheral tissues. TBG (Thyroxine Binding Globulin) is the major carrier of T4. This binding protects T4 from metabolism and excretion resulting in its long half-life in the circulation. Only about 0.03% of total T4 in plasma is unbound. The half-life of elimination of T4 is 6 to 7 days. In hyperthyroidism, the half-life is shortened to 3 or 4 days, whereas in hypothyroidism it may be 9 to 10 days. In conditions associated with reduced protein in plasma as in nephrosis or hepatic cirrhosis or when binding to protein is inhibited by certain drugs the half-life of T4 may be shortened. The liver is the major site of degradation of Thyroid hormones. T4 is conjugated with Glucuronic and Sulphate conjugates through the Phenolic hydroxyl group and excreted in the urine.There is an enterohepatic circulation of the Thyroid hormones, since they are liberated by hydrolysis in the intestine and reabsorbed. Because of the long half-life of T4, a steady blood level of the biologically more active T3 can be obtained from one single daily dose of Levothyroxine. Therefore, variations in the therapeutic effect are unlikely once the correct dosage has been established.Dosage & Administration of Thyrin 50 mcgAdult dose: Initial starting dose: 25-50 meg/day, with gradual increments in dose at 6-8 week intervals, as needed. The Thyrin 50 mcg dose is generally adjusted in 12.5-25 meg increments until the patient with primary hypothyroidism is clinically euthyroid and the serum TSH has normalized. In patients with severe hypothyroidism: Initial dose is 12.5-25 meg/day with increases of 25 meg/day every 2-4 weeks, accompanied by clinical and laboratory assessment,until the TSH level is normalized. In patients with secondary (pituitary) or tertiary (hypothalamic) hypothyroidism: Thyrin 50 mcg dose should be titrated until the patient is clinically euthyroid and the serum free - T4 level is restored to the upper half of the normal range. For patients older than 50 years or for patients under 50 years of age with underlying cardiac disease: 1.7 meg/kg/day. Pediatric Dosage Newborns: The recommended starting dose is 10-15 meg/kg/day. A lower starting dose should be considered in infants at risk for cardiac failure and the dose should be increased in 4-6 weeks as needed based on clinical and laboratory response to treatment. In infants with very low (12 years but growth and puberty incomplete: 2-3 meg/kg/day Growth and puberty complete: 1.7 meg/kg/day. The dose should be adjusted based on clinical response and laboratory parameters. In the treatment of goitres, nodules and Thyroid cancer, the objective is to ensure a constant and sufficient suppression of TSH. For suppression of TSH levels, a gradual increase in dosing is usually not necessary. For adults, the usual suppressive dosage of T4 is 2.6 meg/kg of body weight daily. When Thyrin 50 mcg is used as a diagnostic aid, the dosage depends on the type of investigation.Dosage of Thyrin 50 mcgAdult dose: Initial starting dose: 25-50 mcg/day, with gradual increments in dose at 6-8 week intervals, as needed. The Thyrin 50 mcg dose is generally adjusted in 12.5-25 mcg increments until the patient with primary hypothyroidism is clinically euthyroid and the serum TSH has normalized. In patients with severe hypothyroidism: Initial dose is 12.5-25 mcg/day with increases of 25 mcg/day every 2-4 weeks, accompanied by clinical and laboratory assessment,until the TSH level is normalized. In patients with secondary (pituitary) or tertiary (hypothalamic) hypothyroidism: Thyrin 50 mcg dose should be titrated until the patient is clinically euthyroid and the serum free - T4 level is restored to the upper half of the normal range. For patients older than 50 years or for patients under 50 years of age with underlying cardiac disease: 1.7 mcg/kg/day. Pediatric Dosage (Newborns): The recommended starting dose is 10-15 mcg/kg/day. A lower starting dose should be considered in infants at risk for cardiac failure and the dose should be increased in 4-6 weeks as needed based on clinical and laboratory response to treatment. In infants with very low (12 years but growth and puberty incomplete: 2-3 mcg/kg/day Growth and puberty complete: 1.7 mcg/kg/day. The dose should be adjusted based on clinical response and laboratory parameters.Interaction of Thyrin 50 mcgConcurrent use of tri/tetracyclic antidepressants and Levothyroxine may increase the therapeutic and toxic effects of both drugs, possibly due to increased receptor sensitivity to catecholamines.Toxic effects may include increased risk of cardiac arrhythmias and CNS stimulation; onset of action of tricyclics may be accelerated. Administration of sertraline in patients stabilized on Levothyroxine may result in increased Levothyroxine requirements. Addition of Levothyroxine to antidiabetic or insulin therapy may result in increased antidiabetic agent or insulin requirements. Careful monitoring of diabetic control is recommended, especially when thyroid therapy is started, changed, or discontinued. Serum digitalis glycoside levels may be reduced in hyperthyroidism or when the hypothyroid patient is converted to the euthyroid state. Therapeutic effect of digitalis glycosides may be reduced.Contraindications Untreated subclinical or overt Thyrotoxicosis of any etiology Acute Myocardial Infarction Uncorrected Adrenal failure. Side Effects of Thyrin 50 mcgAdverse reactions associated with Levothyroxine therapy are primarily those of hyperthyroidism due to therapeutic overdose. They include the following: General: Fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating; Central nervous system: Headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia. Musculoskeletal: Tremors, muscle weakness. Cardiovascular: Palpitations, tachycardia, arrhythmias, increased pulse and blood pressure Respiratory: Dyspnea. Gastrointestinal: Diarrhea, vomiting, abdominal cramps. Dermatologic: Hair loss, flushing. Pregnancy & LactationPregnancy Category A. Pregnancy may increase Levothyroxine requirements. Although Thyroid hormones are excreted only minimally in human milk,caution should be exercised when it is administered to a nursing woman.However, adequate replacement doses of Levothyroxine are generally needed to maintain normal lactation.Precautions & Warnings In patients whose hypothyroidism is due to a decrease in pituitary gland function, there may also be adrenocortical insufficiency;before starting Levothyroxine therapy, this should be treated by adequate replacement with Corticosteroids to prevent acute adrenal insufficiency. The choice of the starting dose and of any increases in dosing should be made with great care in patients with cardiovascular disease and/or severe and long-existing hypothyroidism.Too high an initial dose or too rapid an increase in dosing may lead to development or worsening of angina complaints, arrhythmias, myocardial infarction, cardiac failure or to sudden increase in blood pressure, especially in older patients. Any marked change of body weight during treatment with T4 requires adjustment of the dosage. When monitoring blood levels of T3 and T4, it should be borne in mind that a "high" normal to slightly increased T4 level will be necessary in order to obtain a normal level of T3. The correct dosage of Levothyroxine in primary hypothyroidism should generally be established by monitoring the serum level of TSH to see whether it has normalized. Because intoxication with Thyroid preparations may have serious consequences. Overdose Effects of Thyrin 50 mcgThe signs and symptoms of overdose are those of hyperthyroidism - agitation, confusion, irritability, hyperactivity, headache, sweating, mydriasis, tachycardia, arrhythmias, tachypnoea, pyrexia, increased bowel movements and convulsions. Cerebral embolism, shock, coma, and death have been reported. Symptoms may not necessarily be evident or may not appear until several days after ingestion of Thyrin 50 mcg. Dose of Thyrin 50 mcg should be reduced or temporarily discontinued if signs or symptoms of overdosage occur. Treatment is symptomatic.Storage ConditionsStore below 30?C and dry place, protect from light. Keep out of the reach of children.Drug ClassesThyroid drugs & hormoneMode Of ActionThis tablet contains synthetic Levothyroxine (also called Thyroxine or T4) which is identical to the natural hormone T4, produced in the Thyroid gland. About 30% of T4 is converted to the much more active Triiodothyronine (T3) in peripheral tissues. TBG (Thyroxine Binding Globulin) is the major carrier of T4. This binding protects T4 from metabolism and excretion resulting in its long half-life in the circulation. Only about 0.03% of total T4 in plasma is unbound. The half-life of elimination of T4 is 6 to 7 days. In hyperthyroidism, the half-life is shortened to 3 or 4 days, whereas in hypothyroidism it may be 9 to 10 days. In conditions associated with reduced protein in plasma as in nephrosis or hepatic cirrhosis or when binding to protein is inhibited by certain drugs the half-life of T4 may be shortened. The liver is the major site of degradation of Thyroid hormones. T4 is conjugated with Glucuronic and Sulphate conjugates through the Phenolic hydroxyl group and excreted in the urine.There is an enterohepatic circulation of the Thyroid hormones, since they are liberated by hydrolysis in the intestine and reabsorbed. Because of the long half-life of T4, a steady blood level of the biologically more active T3 can be obtained from one single daily dose of Levothyroxine. Therefore, variations in the therapeutic effect are unlikely once the correct dosage has been established.PregnancyPregnancy Category A. Pregnancy may increase Levothyroxine requirements. Although Thyroid hormones are excreted only minimally in human milk,caution should be exercised when it is administered to a nursing woman.However, adequate replacement doses of Levothyroxine are generally needed to maintain normal lactation.Sku: 1736107966-4607
Thyrin50 mcg
₦123.75Original price was: ₦123.75.₦111.10Current price is: ₦111.10. -
SaleTelmidip 5 mg+80 mgThis combination is used for the treatment of essential hypertension in adults. Replacement Therapy:?Patients receiving telmisaitan and amlodipine from separate tablets may instead receive Telmisartan & Amlodipine containing the same component doses.Add-On Therapy: Telmisartan & Amlodipine is indicated in patients whose blood pressure is not adequately controlled on telmisaitan or amlodipine monotherapy.Initial Therapy:?Telmisartan & Amlodipine may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of Telmisartan & Amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Telmisartan & Amlodipine tablets.Patients with moderate or severe hypeitension are at relatively high-risk for cardiovascular events (eg, stroke, heait attacks and heart failure), kidney failure and vision problems, so prompt treatment is clinically relevant. Consider the patient?s baseline blood pressure, the target goals and the incremental likelihood of achieving goals with a combination compared to monotherapy when deciding whether to use Telmisartan & Amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient?s risk.Theropeutic ClassCombined antihypertensive preparationsPharmacologyAmlodipine relaxes peripheral and coronary vascular smooth muscle. It produces coronary vasodilation by inhibiting the entry of Ca ions into the slow channels or select voltage sensitive channels of the vascular smooth muscle and myocardium during depolarisation. It also increases myocardial oxygen delivery in patients with vasospastic angina.Telmisartan is a nonpeptide ATI angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to ATI receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.Dosage & Administration of Telmidip 5 mg+80 mgEach tablet contains Telmisartan 40 mg & Amlodipine 5 mg ?Adults: One tablet should be taken once daily. Maximum Recommendation Dose: two tablets/day.Replacement Therapy: Patients receiving telmisartan and amlodipine from separate tab can instead receive. Telmisartan & Amlodipine containing the same component doses in 1 tablet once daily eg, to enhance convenience or compliance.Add-On Therapy:?Telmisartan & Amlodipine may be administered in patients whose blood pressure is not adequately controlled with amlodipine or telmisartan alone. Patients treated with amlodipine 10 mg who experience any dose-limiting adverse reactions eg, oedema, may be switched to Telmisartan & Amlodipine 40/5 mg once daily, reducing the dose of amlodipine without reducing the overall ected antihypertensive response.Individual dose titration with the components (ie, am odipine and telmisaitan) is recommended before changing to the fixed-dose combination. When clinically appropriate, direct change from monotherapy to the fixed-dose combination may be considered.Initial Therapy:?A patient may be initiated on Telmisartan & Amlodipine if it is unlikely that control of blood pressure would be achieved with a single agent.Usual Starting Dose: 40/5 mg once daily. Initial therapy with Telmisartan & Amlodipine is not recommended in patients 75 years or with hepatic impairment. Correct imbalances on intravascular volume- or salt-depletion, before initiating therapy with Telmisartan & Amlodipine tablet. Telmisartan & Amlodipine may be taken with or without food.Children and Adolescents: Telmisartan & Amlodipine is not recommended for use in patients below 18 years due to a lack of data on safety and efficacy.Elderly:?No dose adjustment is necessary for elderly patients. Limited information is available in the very elderly patients.Interaction of Telmidip 5 mg+80 mgNo interactions between the 2 components of this fixed-dose combinations have been observed in clinical studies. Interactions Common to the Combination: No drug interaction studies have been performed with Telmisartan & Amlodipine and other medicinal products.ContraindicationsHypersensitivity to telmisartan, amlodipine, dihydropyridine derivatives or to any of the excipients of Telmisartan & Amlodipine. Biliary obstructive disorders, severe hepatic impairment & hypotension, cardiogenic shock, left ventricle outflow tract obstuction, haemodynamically unstable heart failure after acute MI.Side Effects of Telmidip 5 mg+80 mgThe most common adverse reactions include Dizziness, peripheral oedema. Somnolence, migraine, headache, paraesthesia, vertigo, bradycardia, palpitations, hypotension, orthostatic hypotension, flushing, cough, abdominal pain, diarrhoea, nausea, pruritus, arthralgia, muscle spasms, myalgia, erectile dysfunction, asthenia, chest pain, fatigue, oedema, increased hepatic enzyme.Pregnancy & LactationPregnancy: Category D. There is positive evidence of human foetal risk, but the benehts from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).Use in lactation:?It is not known whether telmisartan and/or amlodipine are excreted in human milk. Animal studies have shown excretion of telmisartan in breast milk. Because of the potential adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue therapy, taking into account the importance of this therapy for the motherPrecautions & WarningsHepatic & renal impairment, renovascular HTN, intravascular hypovolaemia, severe CHE renal artery stenosis, primary aldosteronism, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, NYHA III & IV heart failure of non-ischaemic aetiology, hyperkalaemia. Fructose intolerance. May impair ability to drive or operate machinery. Children & adolescent 18 years.Impairment of Fertility: No data from controlled clinical studies with the fixed dose combination or with the individual components are available.Separate reproductive toxicity studies with the combination of telmisartan and amlodipine have not been conducted. In preclinical studies, no effects of telmisartan on male and female fertility were observed.? Similarly, no effects on male and female fertility were reported for amlodipine.Storage ConditionsStore in a cool and dry place, protected from light. Keep out of children?s reach.Sku: 1736107962-4606
Telmidip5 mg+80 mg
₦6,600.00Original price was: ₦6,600.00.₦5,940.00Current price is: ₦5,940.00.₦6,600.00Original price was: ₦6,600.00.₦5,940.00Current price is: ₦5,940.00. Add to basket Quick View -
SaleLinax 5 mgLinax 5 mg is prescribed to treat type 2 diabetes mellitus in adults to enhance glycaemic control. As monotherapy: in patients who cannot be properly managed by diet and exercise alone and for whom metformin is contraindicated owing to renal impairment or inappropriate due to intolerance. As monotherapy: in patients who cannot be properly managed by diet and exercise alone and for whom metformin is contraindicated owing to renal impairment or inappropriate due to intolerance. When diet and exercise plus metformin alone are insufficient to achieve adequate glycaemic control, combination therapy may be used. Examples include using sulphonylurea in addition to metformin when diet and exercise plus dual therapy with these drugs is insufficient to achieve adequate glycaemic control.Theropeutic ClassDipeptidyl Peptidase-4 (DPP-4) inhibitorPharmacologyLinax 5 mg is recommended for those with type 2 diabetes mellitus to help with glycemic management. The incretin hormones GLP-1 (glucagon-like peptide-4) and GIP are degraded by the enzyme DPP-4, which is inhibited by it (glucose-dependent insulinotropic polypeptide). By boosting the release of insulin from pancreatic beta () cells in a glucose-dependent manner and inhibiting the release of glucagon from pancreatic alpha () cells into the blood, this raises the concentrations of active incretin hormones.Dosage & Administration of Linax 5 mgYou should take Linax 5 mg once a day. When given along with metformin, you should keep it constant. A lower dose of sulfonylurea may be used in conjunction with another medication to lessen the risk of hypoglycemia. Individuals with renal impairment: No dose modification is necessary. It may be taken at any time of the day with or without food.Dosage of Linax 5 mgYou should take Linax 5 mg once a day. When given along with metformin, you should keep it constant. A lower dose of sulfonylurea may be used in conjunction with another medication to lessen the risk of hypoglycemia. Individuals with renal impairment: No dose modification is necessary. It may be taken at any time of the day with or without food.Interaction of Linax 5 mgThis medication does not inhibit other CYP isozymes but is a weak competitive and weak to moderate mechanism-based inhibitor of the CYP isozyme CYP3A4. It is unlikely that other medications will interact clinically meaningfully with Linax 5 mg, and clinical investigations have shown that the drug has no clinically significant impact on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin, or oral contraceptives.ContraindicationsHypersensitivity to any excipient or active ingredient.Side Effects of Linax 5 mgAlong with metformin and sulfonylurea, there is a chance of hypoglycemia, nasopharyngitis, cough, and pancreatitis.Pregnancy & LactationB-category pregnancy. Pregnant women have not been the subject of sufficient, rigorous investigations. As a result, only use this pills during pregnancy if absolutely necessary. It may or may not enter breast milk; this is unknown.Precautions & WarningsHypersensitivity to any excipient or active ingredient.Storage ConditionsKeep dry and away from heat and light. Keep out of children's reach.Drug ClassesDipeptidyl Peptidase-4 (DPP-4) inhibitorMode Of ActionLinax 5 mg is recommended for those with type 2 diabetes mellitus to help with glycemic management. The incretin hormones GLP-1 (glucagon-like peptide-1) and GIP are degraded by the enzyme DPP-4, which is inhibited by it (glucose-dependent insulinotropic polypeptide). By boosting the release of insulin from pancreatic beta () cells in a glucose-dependent manner and inhibiting the release of glucagon from pancreatic alpha () cells into the blood, Linax 5 mg raises the concentrations of active incretin hormones.PregnancyB-category pregnancy. Pregnant women have not been the subject of sufficient, rigorous investigations. As a result, only use Linax 5 mg pills during pregnancy if absolutely necessary. This medication may or may not enter breast milk; this is unknown.Sku: 1736107960-4605
Linax5 mg
₦4,400.00Original price was: ₦4,400.00.₦3,960.00Current price is: ₦3,960.00.₦4,400.00Original price was: ₦4,400.00.₦3,960.00Current price is: ₦3,960.00. Add to basket Quick View -
SaleLinatab M 2.5 mg+500 mgThis is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both Linagliptin and Metformin Hydrochloride is appropriateTheropeutic ClassCombination Oral hypoglycemic preparationsPharmacologyLinagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (?) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (?) cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.Dosage & Administration of Linatab M 2.5 mg+500 mgLinagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily. In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily. Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.Dosage of Linatab M 2.5 mg+500 mgLinagliptin & Metformin immediate release tablet: The dosage of Linagliptin & Metformin should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin Hydrochloride use.Recommended starting dose: In patients currently not treated with Metformin Hydrochloride, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily. In patients already treated with Metformin Hydrochloride, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily. Patients already treated with Linagliptin and Metformin Hydrochloride, individual components may be switched to this combination containing the same doses of each component.Linagliptin & Metformin extend release tablet: The dosage of this combination should be individualized on the basis of both effectiveness and tolerability, while not exceeding the maximum recommended total daily dose of Linagliptin 5 mg and Metformin Hydrochloride 2000 mg. this combination should be given once daily with a meal.Recommended starting dose: In patients currently not treated with metformin, initiate this combination treatment with 5 mg Linagliptin/1000 mg Metformin Hydrochloride extended-release once daily with a meal.In patients already treated with Metformin, start this combination with 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.In patients already treated with Linagliptin & Metformin immediate release tablet, switch to extend release tablet containing 5 mg of Linagliptin total daily dose and a similar total daily dose of Metformin once daily with a meal.5 mg Linagliptin & 1000 mg Metformin Hydrochloride extended-release tablet should be taken as a single tablet once daily. Patients using 2.5 mg Linagliptin & 1000 mg Metformin extended release tablets should take two tablets together once daily.Interaction of Linatab M 2.5 mg+500 mgCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of this medicine may be reduced when administered in combination.ContraindicationsAlthough Linagliptin undergoes minimal renal excretion, Metformin Hydrochloride is known to be substantially excreted by the kidney. The risk of Metformin Hydrochloride accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin Hydrochloride.Side Effects of Linatab M 2.5 mg+500 mgMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Pregnancy & LactationThere are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Precautions & WarningsIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Linagliptin & Metformin. Temporarily discontinue Linagliptin & Metformin?in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Overdose Effects of Linatab M 2.5 mg+500 mgIn the event of an overdose with this combination the usual supportive measures (i.e. remove unabsorbed material from the gastrointestinal tract, perform clinical monitoring, and institute supportive treatment) should be employed. Removal of Linagliptin by hemodialysis or peritoneal dialysis is unlikely but Metformin Hydrochloride is dialyzable. During controlled clinical trials in healthy subjects, with single doses of up to 600 mg of Linagliptin (equivalent to 120 times the recommended daily dose), there were no dose-related clinical adverse drug reactions. Overdose of Metformin Hydrochloride has occurred in case of ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with Metformin Hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of Metformin Hydrochloride overdose cases.Storage ConditionsKeep in a cool & dry place (below 30?C), protected from light & moisture. Keep out of the reach of children.Drug ClassesCombination Oral hypoglycemic preparationsMode Of ActionLinagliptin is indicated to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta (?) cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha (?) cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin Hydrochloride decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.PregnancyThere are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Sku: 1736107954-4604
Linatab M2.5 mg+500 mg
₦6,600.00Original price was: ₦6,600.00.₦5,940.00Current price is: ₦5,940.00.₦6,600.00Original price was: ₦6,600.00.₦5,940.00Current price is: ₦5,940.00. Add to basket Quick View -
SaleBiltin 20 mgBiltin 20 mg is indicated for symptomatic treatment of allergic rhino-conjunctivitis (seasonal and perennial) and urticaria.Theropeutic ClassNon-sedating antihistaminesPharmacologyBiltin 20 mg is a non-sedative H1 receptor selective antagonist. Its principal effects are mediated via selective inhibition of peripheral H1-receptors. It shows moderate to high affinity for histamine H1-receptors and no affinity for muscarinic, serotonergic, dopaminergic and noradrenergic receptors.Dosage & Administration of Biltin 20 mgChildren between 6 to 11 years: 10 mg mouth dissolving tablet for the symptomatic relief of allergic rhinitis, allergic rhinoconjunctivitis and urticaria. The Mouth dissolving tablet is for oral use only. It should be placed in the mouth. It will disperse rapidly in saliva and can be easily swallowed. Alternatively, the mouth dissolving tablet can be dispersed in a tea spoon of water before being swallowed by the children. The maximum recommended daily dose for children in between 6 to 11 years is 10 mg Biltin 20 mg mouth dissolving tablet (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken.Adults & adolescents (12 years of age and over): 20 mg tablet once daily for symptomatic relief of allergic rhinitis, urticaria and allergic rhinoconjunctivitis. The maximum recommended daily dose is 20 mg Biltin 20 mg (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken. 20 mg Biltin 20 mg tablet (1 tablet) once daily should be swallowed with water on an empty stomach to achieve optimal exposure to Biltin 20 mgDosage of Biltin 20 mgAdults & adolescents (12 years of age and over): 20 mg tablet once daily for symptomatic relief of allergic rhinitis, urticaria and allergic rhinoconjunctivitis. The maximum recommended daily dose is 20 mg Biltin 20 mg (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken. 20 mg Biltin 20 mg tablet (1 tablet) once daily should be swallowed with water on an empty stomach to achieve optimal exposure to Biltin 20 mg.Children between 6 to 11 years: 10 mg mouth dissolving tablet for the symptomatic relief of allergic rhinitis, allergic rhinoconjunctivitis and urticaria. The Mouth dissolving tablet is for oral use only. It should be placed in the mouth. It will disperse rapidly in saliva and can be easily swallowed. Alternatively, the mouth dissolving tablet can be dispersed in a tea spoon of water before being swallowed by the children. The maximum recommended daily dose for children in between 6 to 11 years is 10 mg Biltin 20 mg mouth dissolving tablet (1 tablet) and should not be exceeded. If a dose is missed, the next scheduled dose should be taken. An extra dose should not be taken.Children between 2 to 11 years: 4 ml once daily.Interaction of Biltin 20 mgConcomitant intake of Biltin 20 mg and Ketoconazole or Erythromycin or Diltiazem increased C max of Biltin 20 mg. The psychomotor performance after concomitant intake of alcohol and Biltin 20 mg was similar to that observed after intake of alcohol and placebo. Concomitant intake of Biltin 20 mg and Lorazepam 3 mg for 8 days did not potentiate the depressant CNS effects of Lorazepam.ContraindicationsBiltin 20 mg is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients of the tablet.Side Effects of Biltin 20 mgThe most commonly reported side effects in clinical trial are headache, dizziness, somnolence and fatigue. These adverse events occurred with a comparable frequency in patients receiving placebo.Pregnancy & LactationThere are no adequate or limited amount of data for the use of Biltin 20 mg in pregnant women and during breast feeding and on the effects on fertility. In case of pregnancy or breast feeding, Biltin 20 mg should be avoided during pregnancy, unless advised otherwise by a physician.Precautions & WarningsCo-administration of Biltin 20 mg and P-glycoprotein inhibitors (e.g. Ketoconazole, Erythromycin, Cyclosporine, Ritonavir or Diltiazem) should be avoided in patients with moderate or severe renal impairment.Overdose Effects of Biltin 20 mgIn clinical trials, after administration of Biltin 20 mg at doses 10 to 11 times the therapeutic dose (220 mg as single dose; or 200 mg/day for 7 days) frequency of treatment-emergent adverse events was two times higher than with placebo. The adverse reactions most frequently reported were dizziness, headache and nausea. No serious adverse events and no significant prolongation in the QTc interval were reported.Storage ConditionsKeep below 30?C temperature, protected from light and moisture. Keep out of reach of children.Use In Special PopulationsUse in patients with impaired hepatic & renal function: There is no clinical experience in patients with hepatic impairment. Since Biltin 20 mg is not metabolized and renal clearance is its major elimination route, hepatic impairment is not expected to increase the systemic exposure above the safety margin. Therefore, no dosage adjustment is required in patients with hepatic impairment. No dosage adjustment is required in patients with renal impairment.Geriatrics (>65 years of age): No dosage adjustments are necessary in patients over 65 years.Pediatrics (<6 years of age): The safety and efficacy of Biltin 20 mg in children under 6 years of age have not been established.Drug ClassesNon-sedating antihistaminesMode Of ActionBiltin 20 mg is a non-sedating, long-acting histamine antagonist with selective peripheral H 1 receptor antagonist affinity and no affinity for muscarinic receptors. Biltin 20 mg inhibits histamine-induced wheal and flare skin reactions for 24 hours following single doses.PregnancyThere are no or limited amount of data from the use of Biltin 20 mg in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity, parturition or postnatal development. As a precautionary measure, it is preferable to avoid the use of Biltin 20 mg during pregnancy. The excretion of Biltin 20 mg in milk has not been studied in humans. A decision must be made taking into account the benefit of breast-feeding for the child and the benefit of Biltin 20 mg therapy for the mother.Pediatric UsesEfficacy and safety of Biltin 20 mg in children under 2 years of age have not been established and there is little clinical experience in children aged 2 to 5 years, therefore Biltin 20 mg should not be used in these age groups.Sku: 1736107951-4603
Biltin20 mg
₦825.00Original price was: ₦825.00.₦750.75Current price is: ₦750.75.